



VILIN BIO MED LIMITED

An ISO 9001-2008 & GMP certified Company

August 23, 2024

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

Subject: Submission of Annual Report for The Financial Year 2023-24

Ref: i). Disclosure under Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

ii). NSE Symbol- VILINBIO ISIN: INE0L4V01013

Dear Sir/Madam,

In terms of Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit a copy of the Annual Report of the Company for the Financial Year 2023-24, including Notice of 18th Annual General Meeting (“AGM”) of the members of the Company, scheduled to be held on Saturday, September 21, 2024 at 11.30 A.M. (“IST”) Video Conferencing /Other Audio-Visual Means (“VC/OAVM”).

Kindly take the same on record.

Thanking You

Yours Faithfully

For Vilin Bio Med Limited

Viswa Prasad Sadhanala
Director

Encl.: As above

Registered Office: Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Hyderabad – 500009, Telangana.
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar- 247667, Uttarakhand.

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

E-mail: cs@vilinbiomed.co.in

GST: 36AACCV1433D1ZR

Website: www.vilinbiomed.co.in

Vilin Bio Med Limited
18th Annual Report
2023-2024

INDEX

SI No	Particulars	Page Nos.
I	Corporate Information	03
II	Notice of the 18th Annual General Meeting	04-14
III	Board's Report	15-22
IV	Annexures	23-32
V	Independent Auditor's Report	33-41
VI	Standalone Financial Statements	42-66

BOARD OF DIRECTORS:

Mr. Veerareddy Vallapureddy
Ms. Aruna Madishetti
Mr. Viswa Prasad Sadhanala
Mr. Anuj Bajpai

Independent Director
Independent Director
Managing Director
Whole-Time Director

KEY MANAGERIAL PERSONNEL:

Mr. Chilam Srikanth
Mr. Anand Lohia

Chief Financial Officer
Company Secretary & Compliance Officer

REGISTERED OFFICE:

Sy. No. 115/GF/J, Hanumanji Colony
Brig Sayeed Road, Bowenpally
Secunderabad-500009 Telangana
E-mail: cs@vilinebiomed.co.in
Website: www.vilinebiomed.co.in
Tel No.: 040-7961 8843

MANUFACTURING UNIT:

Unit-II, Khasra No. 85, Madhopur Village, Roorkee
Haridwar, Uttarakhand

STATUTORY AUDITORS:

M/s PPKG & Co
Chartered Accountants

SECRETARIAL AUDITORS:

M/s Kashinath Sahu & Co
Company Secretaries

REGISTRAR & SHARE TRANSFER AGENTS (RTA):

M/s Bigshare Services Private Limited
#306, 3rd Floor, Right Wing, Amrutha Ville
Somajiguda, Rajbhavan Road
Hyderabad – 500082, Telangana
E-mail: bsshyd@bigshareonline.com
Website: www.bigshareonline.com

LISTING:

Listed on NSE SME Board
(EMERGE Platform)

BANKER TO THE COMPANY:

Punjab National Bank
ICICI Bank

NOTICE

Notice is hereby given that the Eighteenth Annual General Meeting of the Members of M/s Vilin Bio Med Limited ("the Company") will be held on Saturday, September 21, 2024 at 11:30 A.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM") to transact following business mentioned below:

Ordinary Business:

1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended March 31, 2024, together with the Report of the Directors and Auditors thereon and in this regard, to give assent or dissent to the following Resolution as an Ordinary Resolution:

"**RESOLVED THAT** the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2024 including the Audited Balance Sheet as at March 31, 2024, the Statement of Profit and Loss for the year ended on that date and the Reports of the Board of Directors and Auditors thereon, be and are hereby received, considered and adopted."

Special Business

2. Regularization of the Appointment of Ms. Aruna Madishetti (DIN: 10746293), Additional Director as an Independent Director.

To consider and, if thought fit, to pass with or without modification, the following resolution as Special Resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 149, 150, 152 read with Schedule – IV and other applicable provisions of the Companies Act, 2013 ('the Act') and the Companies (Appointment and Qualifications of Directors) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and as amended from time to time, of Ms. Aruna Madishetti (DIN: 10746293), who was appointed as an Additional Director- Independent of the Company with effect from August 22, 2024 by the board of directors on the recommendation of the Nomination and Remuneration Committee and who holds office up to the date of this Annual General Meeting of the Company in terms of Section 161(1) of the Act and in respect of whom the Company has received a notice in writing from a member under Section 160(1) of the Act proposing his candidature for the office of Director of the Company and also a written declaration in conformity with SEBI (LODR) Regulations, 2015, be and is hereby appointed as Director of the Company under Independent Category of the company, not liable to retire by rotation, for a First Term of five (5) consecutive years commencing from August 22, 2024 up to August 21, 2029

"**RESOLVED FURTHER THAT** the Board of Directors of the Company (including its Committee thereof) be and is hereby authorised to do all such acts, deeds, matters and things as required, expedient and desirable for the purpose of giving effect to the Resolution."

**By Order of the Board
For Vilin Bio Med Limited**

**Date: August 22, 2024
Place: Hyderabad**

**Sd/-
Anand Lohia
Company Secretary**

NOTES:

1. The details as required under Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') entered with the Stock Exchanges and Secretarial Standard on General Meeting (SS-2) in respect of the Directors seeking appointment / re-appointment at this Annual General Meeting is annexed.
2. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 is annexed.
3. In continuation to the MCA General Circular No. 10/2022 dated December 28, 2022 and General Circular No. 09/2023 dated September 25, 2023 has decided to allow the Companies to conduct their AGMs on or before September 30, 2024, in accordance with the requirements laid down in paragraphs 3 and 4 of the General Circular No. 20/ 2020 dated May 5, 2020. As per the said General Circular dated May 5, 2020, in view of the prevailing situation, owing to the difficulties involved in dispatching of physical copies of the Financial Statements (including Board's Report, Auditor's Report or other documents required to be attached therewith), such statements along with Notice of the Meeting shall be sent only by e-mail to the Members and to all other persons so entitled. With this facility, the Companies are allowed to conduct their AGM through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Hence, in compliance with the MCA Circulars and SEBI Circulars, the 18th Annual General Meeting of the Company is being held through VC / OAVM on Saturday, September 21, 2024 at 11:00 A.M. (IST).

In compliance of Section 20 of the Companies Act, 2013 and further to the aforesaid MCA Circulars and SEBI Circulars, Notice of the 18th Annual General Meeting along with the Annual Report 2023-2024 is being sent only through electronic mode to the Members whose e-mail addresses are registered with the Company/Depositories. Members may note that the Notice and the Annual Report 2023-2024 will also be available on the Company's Website: <http://www.vilinbiomed.co.in/> and Website of the Stock Exchange i.e., National Stock Exchange Limited: <https://www.nseindia.com>, and on the Website of CDSL: <https://www.eVotingindia.com>

4. Green Initiative: To support the Green Initiative, Members who have not registered their e-mail address are requested to register their e-mail address for receiving all the communications including Annual Report, Notices, Circulars etc. from the Company electronically.
5. A Member entitled to attend and vote at the AGM is entitled to appoint a Proxy to attend and vote on his / her behalf and the Proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of Proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
6. Members of the Company under the category of Institutional Investors are encouraged to attend and vote at the AGM through VC/OAVM. Corporate Members intending to authorize their Representatives to participate and vote at the AGM are requested to upload a copy of the Board Resolution/Authorization Letter on the E-Voting Portal or send to the Company at cs@vilinbiomed.co.in.
7. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the Quorum under Section 103 of the Act. As per Regulation 40 of the SEBI Listing Regulations, as amended, Securities of Listed Entities can be transferred only in Dematerialised form with effect from April 1 2019, except in case of transmission or transposition of Securities. In view of this, Members holding Shares in Physical Form are requested to consider converting their holdings to Dematerialised form. Members can contact M/s Bigshare Services Private Limited, Registrar and Share Transfer Agents of the Company, ("RTA" or "Registrar") situated at 306, Right Wing, 3rd Floor, Amrutha Ville, Somajiguda, Rajbhavan Road, Hyderabad – 500082, E-mail: bsshyd@bigshareonline.com and website of the Registrar: www.bigshareonline.com for assistance in this regard.
8. Members are requested to intimate changes, if any, pertaining to their Name, Postal Address, E-mail Address, Telephone/Mobile Numbers, Permanent Account Number, Mandates, Nominations, Power of Attorney, Bank Details viz., Name of the Bank, Branch Details, Bank Account Number, MICR Code, IFSC Code etc., to their Depository Participants ("DPs") in case the Shares are held in Electronic Form and Registrar/RTA in case the Shares are held in Physical Form.
 - a. Registration of E-mail for Shareholders holding Physical Shares: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with

- the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail and also upload the image of Share Certificate in PDF or JPEG format. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification. For Permanent Registration for Demat Shareholders: It is clarified that for permanent registration of E-mail address, Members are requested to register their E-mail address, in respect of Demat holdings with the respective Depository Participant (DP) by follow the procedure as prescribed by the Depository Participant.
- b. For Temporary Registration for Demat Shareholders: Members holding Shares in Physical Form and who have not registered their E-mail addresses may get their E-mail addresses registered with the Registrar, by referring to their website: www.bigshareonline.com and follow the Registration Process as guided therein. Members are requested to provide details such as Name, Folio Number, Certificate Number, PAN, Mobile Number and E-mail.
 - c. Registration of Bank Details for Physical Shareholders: Members holding Shares in Physical Form and who have not registered their Bank details can get the same registered with the Registrar, by clicking the www.bigshareonline.com and follow the registration process as guided therein. Members are requested to provide details such as Name, Folio Number, Share Certificate Number, PAN, E-mail, along with the copy of the Cheque Leaf with the First named Member as mentioned on the Cheque Leaf containing Bank Name and Branch, Type of Account, Bank Account Number, MICR Details and IFSC code in PDF or JPEG format. It is very important that the Member should submit the request letter duly signed. The Registrar will verify the documents upload and will only take on records for all valid cases. On submission of the details, an OTP will be received by the Member which needs to be entered in the link for verification.
9. The Register of Members and Share Transfer Books of the Company will remain closed from September 18, 2024 to September 21, 2024 (both days inclusive).
 10. Nomination: Pursuant to Section 72 of the Companies Act, 2013, Members holding Shares in Physical Form are advised to file Nomination in the prescribed Form SH-13 with the Company's Share Transfer Agent. In respect of the Shares held in Dematerialised form, Members may please contact their respective Depository Participant.
 11. Consolidation of Physical Share Certificates: Members holding Shares in Physical Form, in identical order of Names, in more than One Folio are requested to send to the Company or Registrar, the details of such Foliros together with the Share Certificates for consolidating their holdings in One Folio. A Consolidated Share Certificate will be issued to such Members after making requisite changes.
 12. In compliance with the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI Listing Regulations, the Company has provided a facility to its Members to cast their vote electronically, through the E-Voting services provided by Central Depository Services (India) Limited ("CDSL") on all the Resolutions set forth in this Notice. Members who have cast their Votes by Remote E-Voting prior to the AGM may also participate in the AGM through VC but shall not be entitled to cast their Vote on such Resolutions again. The manner and process of E-Voting remotely by Members is provided in the instructions for E-Voting which forms part of this Notice.
 13. A Person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date for dispatch of Notice and Annual Report i.e., August 23, 2024 will only be entitled for receipt of Annual Report.
 14. The Voting Rights of the Shareholders for Voting through Remote E-Voting at the AGM shall be in proportion to their share of the Paid-up Equity Shares of the Company as on Saturday, 14th September, 2024 (**Cut-off Date**). A Person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off Date, only shall be entitled to avail the facility of Remote E-Voting or of Voting at the AGM and who is not a Member as on the Cut-off Date shall treat this Notice for information purposes only.

15. The Remote E-Voting Period will commence on **Wednesday, 18th September, 2024 (IST 9:00 A.M.) and will end on Friday, 20th September, 2024 (IST 5:00 P.M.)**. During this period, Members of the Company holding Shares in Dematerialised form, as on the Cut-off Date i.e., on Saturday, 14th September, 2024 ('Cut-off Date') shall be entitled to cast their vote by Remote E-Voting. Once the Vote on a Resolution is cast by the Member, the Member shall not be allowed to change it subsequently.
16. The facility for Voting during the AGM will also be made available. Members present in the AGM through VC and who have not cast their Vote on the Resolutions through Remote E-Voting and are otherwise not barred from doing so, shall be eligible to Vote through E-Voting system during the AGM.
17. Any person who becomes a Member of the Company after sending the Notice and holding Shares as on the **Cut-off Date (Saturday, 14th September, 2024)** may obtain the Login-id and Password by sending a request at helpdesk.eVoting@cdslindia.com However, if a Member is already registered with CDSL for Remote E-Voting then he/she can use his/her existing User-id and Password for casting the Vote.
18. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through Remote E-Voting.
19. Members seeking any information with regard to the accounts or any matter to be placed at the AGM, are requested to write to the Company mentioning their Name, Demat Account Number/Folio Number, E-mail, Mobile Number at cs@vilinbiomed.co.in on or before **Monday, 16th September, 2024**. The same will be replied by the Company suitably.
20. In case of Joint holders, the Joint holder who is higher in the order of Names, will be entitled to vote at the Meeting, if not already voted through Remote E-Voting.
21. The Board of Directors has appointed Mr. Kashinath Sahu, Practicing Company Secretary, Hyderabad as the Scrutinizer to scrutinize the Remote E-Voting Process and Voting during the AGM, in a fair and transparent manner.
22. The Scrutinizer shall immediately, after the conclusion of E-Voting at the AGM, first count the Votes Cast during the AGM, thereafter, unblock the Votes Cast through Remote E-Voting and make, not later than 2 working dates of conclusion of the AGM, a consolidated Scrutinizer's Report of the Total Votes Cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same. The Results declared along with the Scrutinizer's Report shall be placed on the Website of the Company and on the Website of CDSL immediately. The results will also be communicated to NSE Limited, where the Shares of the Company are listed.
23. To prevent fraudulent transactions, Members are advised to exercise Due Diligence and notify the Company of any change in address or Demise of any Member as soon as possible. Members are also advised not to leave their Demat account(s) dormant for long. Periodic Statement of Holdings should be obtained from the concerned DPs and Holdings should be verified from time to time.
24. **Instructions for attending the AGM through VC / OAVM:**
 - a. Shareholder will be provided with a facility to attend the AGM through VC/OAVM through the CDSL E-Voting system. Shareholders may access the same at <https://www.eVotingindia.com> under Shareholders / Members login by using the Remote E-Voting credentials. The link for VC/OAVM will be available in Shareholder / Members login where the EVSN of the Company is displayed.
 - b. Members may join the Meeting through Laptops, Smartphones, Tablets and I-Pads for better experience. Further, Members will be required to use the Internet with a good speed to avoid any disturbance during the Meeting. Please note that participants connecting from Mobile Devices or Tablets or through Laptops connecting via mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any glitches.
 - c. Shareholders who would like to express their views / ask questions during the Meeting may register themselves as a speaker by sending their request in advance before **Monday, 16th September, 2024 (5:00 P.M.)** from their registered E-mail address mentioning their names, DP-ID and ClientID / Folio Number, PAN and Mobile Number at cs@vilinbiomed.co.in. Only those Members who have pre-registered themselves as a speaker will be allowed to express their views / ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

- d. Members are encouraged to submit their questions in advance with regard to the Financial Statements or any other matter to be placed at the 18th Annual General Meeting, from their registered E-mail address, mentioning their Name, DP-ID and Client-ID Number / Folio Number and Mobile Number, to reach the Company's E-mail address at cs@vilinebiomed.co.in before **Monday, 16th September, 2024 (5:00 P.M.)**. Such questions by the Members shall be suitably replied by the Company.
 - e. Those Shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the Meeting. If any votes are cast by the Shareholders through the E-Voting available during the AGM and if the same Shareholders have not participated in the Meeting through VC / OAVM facility, then the votes cast by such Shareholders shall be considered as invalid, as the facility of E-Voting during the Meeting is available only to the Shareholders attending the Meeting.
25. Subject to the receipt of Requisite number of Votes, the Resolutions forming part of the AGM Notice shall be deemed to be passed on the date of the AGM. Voting through Electronic Means: Pursuant to Section 108 of the Companies Act, 2013 and Rule 20 read with the Companies (Management and Administration) Rules, 2014 read with amendments or re-enactments made thereunder and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is pleased to provide the facility to exercise Members' Right to Vote at the 18th Annual General Meeting (AGM) by electronic means and the business may be transacted through E-Voting Services provided by Central Depository Services (India) Limited (CDSL). The Members attending the Meeting, who have not already cast their vote through Remote E-Voting shall be able to exercise their Voting Rights at the Meeting. The Members who have already cast their vote through Remote E-Voting may attend the Meeting but shall not be entitled to cast their vote again at the AGM.
26. The instructions for Shareholders for Voting Electronically are as under:
- (i) **The Voting Period commences on Wednesday, 18th September, 2024 (9:00 A.M.) and closes on Friday, 20th September, 2024 (5:00 P.M.)** During this period, the Shareholders of the Company, holding Shares in Dematerialized Form, as on the Cut-off Date (Record Date), Saturday, 14th September, 2024 may cast their vote electronically. The E-Voting Module shall be disabled by CDSL for Voting thereafter.
 - (ii) Shareholders who have already voted prior to the Meeting Date would not be entitled to Vote at the Meeting.

Login method for E-Voting and Joining Virtual Meetings for Individual Shareholders holding Securities in Demat Mode:

Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/ CIR/P/2020/242 dated 9th December 2020 on "E-Voting Facility provided by Listed Companies", Individual Shareholders holding Securities in Demat mode are allowed to cast their vote through their Demat Account maintained with the Depositories and Depository Participants. Shareholders are advised to update their Mobile Number and E-mail in their Demat Accounts in order to access the E-Voting Facility. Pursuant to the above said SEBI Circular, Login method for E-Voting and joining Virtual Meetings for Individual Shareholders holding Securities in Demat mode CDSL/NSDL is given below:

Type of Shareholders	Login Method
<p>Individual Shareholders Holding Securities in Demat Mode with CDSL Depository</p>	<ol style="list-style-type: none"> 1. Users who have opted for CDSL EASI / EASIEST facility, can login through their existing User-id and Password. Option will be made available to reach E-Voting page without any further authentication. The URL for Users to login to EASI / EASIEST are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System MYEASI. 2. After successful login to the EASI/EASIEST User will be able to see the E-Voting option for eligible Companies where the E-Voting is in progress as per the information provided by Company. On clicking the E-Voting option, the User will be able to see E-Voting page of the E-Voting Service Provider for casting your Vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting. Additionally, there are also links provided to access the system of all E-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME so that the User can visit the E-Voting Service Providers website directly. 3. If the user is not registered for EASI/ EASIEST, option to register is available at CDSL website www.cdslindia.com To login click on login & New System MYEASI Tab and then click on registration option. 4. Alternatively, the User can directly access E-Voting Page by providing Demat Account Number and PAN on E-Voting link available on www.cdslindia.com homepage. The system will authenticate the User by sending OTP on the Registered Mobile and E-mail as recorded in the Demat Account. After successful authentication, the User will be able to see the E-Voting option where the E-Voting is in progress and also able to directly access the system of all the E-Voting Service Providers.
<p>Individual Shareholders Holding Securities in Demat Mode with NSDL Depository</p>	<ol style="list-style-type: none"> 1. If you are already registered for NSDL 'IDeAS' facility, please visit the E-services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com either on a Personal Computer or on a Mobile. Once the Homepage of E-services is launched Click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' Section. A new screen will open. You will have to enter your User-id and Password. After successful authentication, you will be able to see E-Voting Services. Click on "Access to E-Voting" under E-Voting Services and you will be able to see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be re-directed to E-Voting Service Provider website for casting your vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.

	<ol style="list-style-type: none"> 2. If the User is not registered for IDEAS E-services, option to register is available at https://eservices.nsd.com/ Select "Register Online for IDEAS" Portal or Click at https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp 3. Visit the E-Voting website of NSDL. Open web browser by typing the following URL: https://www.eVoting.nsd.com/ either on a Personal Computer or on a mobile. Once the homepage of E-Voting system is launched, click on the icon "Login" which is available under 'Shareholder / Member' section. A new screen will open. You will have to enter your User-id (i.e. your sixteen-digit Demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository Site wherein you can see E-Voting page. Click on Company name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your Vote during the Remote E-Voting period or joining Virtual Meeting and Voting during the Meeting.
<p>Individual Shareholders Holding Securities in Demat Mode Login through their Depository Participants (DP)</p>	<p>You can also login using the login credentials of your Demat account through your Depository Participant registered with NSDL/CDSL for E-Voting facility. After Successful login, you will be able to see E-Voting option. Once you click on E-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see E-Voting feature. Click on Company Name or E-Voting Service Provider name and you will be redirected to E-Voting Service Provider Website for casting your vote during the remote E- Voting period or joining Virtual Meeting and Voting during the Meeting</p>

Important note: Members who are unable to retrieve User-id/ Password are advised to use Forgot User-id and Forgot Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding Securities in Demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
<p>Individual Shareholders holding the Securities in Demat Mode with CDSL</p>	<p>Members facing any technical issue in login can contact CDSL Helpdesk by sending request at the following E-Mail: helpdesk.evoting@cdslindia.com or Contact at Toll Free No. 1800 22 5533</p>
<p>Individual Shareholders holding the Securities in Demat Mode with NSDL</p>	<p>Members facing any technical issue in login can contact NSDL Helpdesk by sending a request at evoting@nsdl.co.in or Call at Toll Free No. 1800 10 20990 and 1800 22 4430</p>

Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode

- i. The Shareholders should log on to the E-Voting Website: www.evotingindia.com
- ii. Click on "SHAREHOLDERS" Module.
- iii. Now enter your User-id
 - i. For CDSL: 16 Digits Beneficiary ID
 - ii. For NSDL: 8 Character DP-ID followed by 8 Digits Client-ID
 - iii. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- iv. Next enter the 'Image Verification' as displayed and Click on Login.
- v. If you are holding Shares in Demat form and had logged on to www.evotingindia.com and had voted on an earlier E-Voting of any Company, then your existing password is to be used.
- vi. If you are a first-time user follow the steps given below:

For Physical Shareholders and other than Individual Shareholders holding Shares in Demat Form

PAN	Enter your 10-digit alpha-numeric PAN issued by Income Tax Department (Applicable for both Demat Shareholders as well as Physical Shareholders) Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company /RTA or contact Company/RTA
Dividend Bank Details or Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your Demat Account or in the Company Records in order to login. If both the details are not recorded with the Depository or Company, please enter the Member-id /Folio Number in the 'Dividend Bank Details' field.

- vii. After entering these details appropriately, click on 'SUBMIT' tab.
- viii. Shareholders holding Shares in Physical Form will then directly reach the Company selection screen. However, Shareholders holding Shares in Demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the 'New Password' field. Kindly note that this password is to be also used by the Demat Holders for Voting for Resolutions of any other Company on which they are eligible to vote, provided that the Company opts for E-Voting through CDSL Platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- ix. For Shareholders holding shares in Physical Form, the details can be used only for E-Voting on the Resolutions contained in this Notice.
- x. Click on the EVSN of the relevant Company (**Vilin Bio Med Limited**) on which you choose to vote.
- xi. On the Voting Page, you will see 'RESOLUTION DESCRIPTION' and against the same the option 'YES/NO' for Voting. Select the option 'YES' or 'NO' as desired. The option 'YES' implies that you assent to the Resolution and option 'NO' implies that you dissent to the Resolution.
- xii. Click on the 'RESOLUTIONS FILE LINK' if you wish to view the entire Resolution details.
- xiii. After selecting the Resolution, you have decided to vote on, click on 'SUBMIT'. A Confirmation Box will be displayed. If you wish to confirm your vote, click on 'OK', else to change your vote, click on 'CANCEL' and accordingly modify your vote.
- xiv. Once you 'CONFIRM' your vote on the resolution, you will not be allowed to modify your Vote.
- xv. You can also take a print of the votes cast by clicking on 'Click here to Print' option on the Voting Page.

xvi. If a Demat Account Holder has forgotten the login password then enter the User-id and the 'Image Verification Code' and click on Forgot Password and enter the details as prompted by the system.

xvii. Additional Facility for Non – Individual Shareholders and Custodians – For Remote Voting:

- Non – Individual Shareholders (i.e. Other than Individuals, HUF, NRI etc.) and Custodians are required to log on to the website: www.evotingindia.com and register themselves in the 'CORPORATES' Module.
- A Scanned copy of the Registration Form bearing the Stamp and Sign of the Entity should be mailed to helpdesk.evoting@cdslindia.com
- After receiving the login details, a Compliance User should be created using the Admin login and Password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The List of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- It is mandatory that a Scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the Scrutinizer to verify the same.
- Alternatively Non-Individual Shareholders are required to send the relevant Board Resolution/Authority Letter etc. together with the Attested Specimen Signature of the Duly Authorized Signatory who are authorized to vote, to the Scrutinizer and to the Company at the E-mail address: cs@vilinebiomed.co.in if they have voted from individual tab and not uploaded same in the CDSL E-Voting System for the Scrutinizer to verify the same.

If you have any queries or issues regarding E-Voting from the CDSL E-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022-23058738 and 022-23058542/43

All grievances connected with the facility for Voting by electronic means may be addressed to Shri Rakesh Dalvi, Sr Manager, Central Depository Services (India) Limited (CDSL), Wing-A, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai-400013 or send an E-mail to helpdesk.evoting@cdslindia.com or call on 022-23058542/43

**By Order of the Board
For Vilin Bio Med Limited**

**Date: August 22, 2024
Place: Hyderabad**

**Sd/-
Anand Lohia
Company Secretary**

Explanatory Statement

The following Statement sets out all the material facts relating to Special Business in Item No. 2 pursuant to provisions of Section 102(1) of the Companies Act, 2013 mentioned in the accompanying Notice:

Ms. Aruna Madishetti (DIN: 10746293) was appointed as an Additional Director with effect from August, 22, 2024 by the Board of Directors on the recommendation of the Nomination and Remuneration Committee and in accordance with the provisions of the Section 161 of the Companies Act, 2013 and the said Director holds office until the conclusion of 18th Annual General Meeting. The Company has received Notice from a Shareholder under Section 160 of the Companies Act, 2013 proposing the appointment of Ms. Aruna Madishetti (DIN: 10746293), as Director of the Company. Ms. Aruna Madishetti, MBA in Finance possess the required skills, knowledge in Finance & Accounts and it would be beneficial to the Company if she is on the Board of Directors of the Company

Further, the Board of Directors as per the recommendation of the Nomination and Remuneration Committee has proposed to appoint him as Independent Director for the First Term for a period of 5 (five) years pursuant to the provisions of Sections 149, 150, 152 read with Schedule-IV and other applicable provisions of the Companies Act, 2013 (the Act) on the Company Board and the Company will be benefited out of her expertise and can contribute the strategic guidance in the Financial matters of the Company.

None of the Directors of the Company is in any way concerned or interested in the said Resolution except Ms. Aruna Madishetti is concerned in the said Resolution. The Board recommends the said Special Resolution to be passed as set out in the Item No. 2 of the Notice of the AGM

The Board recommends the Resolution for approval of the Members as a Special Resolution as set out in the Item No. 2 of the Notice.

Disclosure under Secretarial Standard - 2, issued by the Institute of Company Secretaries of India is detailed in the Annexure – A to the Notice.

ANNEXURE - A

Details of Director seeking appointment at the 18th Annual General Meeting to be held on September 21, 2024 pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 for General Meetings (SS-2) are as mentioned below:

Name	Ms. Aruna Madishetti
DIN	10746293
Date of Birth	2nd May, 1988
Date of First Appointment to the Board	22nd August, 2024
Designation	Non-Executive Director
Qualification	MBA Finance; B. Com
Brief Resume, Nature of Expertise and skill set in specific functional areas	Ms. Aruna Madishetti has been appointed as Non-Executive Director of our Company. She has a rich experience of ten years in Finance, Accounting and Management.
Shareholding (as on the date of this Notice) in the Company either directly or in form of beneficial interest for any other person	Nil
Relationship with other Directors / KMP's	None of the Directors / KMP's are related
Number of Meetings of the Board attended during the year	Nil
Directorships held in other Companies (excluding Foreign Companies)	Nil
Listed Companies from which the person has resigned from the Directorship in the past three years	Nil
Membership/ Chairmanship of Committees of other Companies	Nil
Remuneration (including Sitting Fees, if any) last drawn	Nil
Terms and conditions of Appointment	As per the Resolution No. 3 of the Notice read with the Explanatory Statement, Ms. Aruna Madishetti is proposed to be appointed as an Independent Director of the Company

**By Order of the Board
For Vilin Bio Med Limited**

**Date: August 22, 2024
Place: Hyderabad**

**Sd/-
Anand Lohia
Company Secretary**

BOARD'S REPORT

Dear Members,

The Directors have pleasure in presenting the 18th Annual Report of the Company, together with the Audited Accounts for the Financial Year ended 31st March, 2024

Financial Highlights

Particulars	(Rs. in Lakhs)	
	2023-2024	2022-2023
Sales	1,580.49	1,231.30
Other Income	32.43	2.44
Total Income	1,612.92	1,233.74
Total Expenses	1,590.41	1,055.58
Profit / (Loss) Before Tax	22.52	178.16
Current Tax	5.11	52.83
Deferred Tax	1.16	0.84
Profit / (Loss) After Tax	16.24	124.50

State of Company Affairs

The Company's Revenues stood at Rs.1,580.49 Lakhs During the year under review, PAT at Rs.16.24 Lakhs as against the corresponding Previous Year, there was Revenue of Rs.1,231.30 Lakhs and the PAT was Rs.124.50 Lakhs. Your directors are exploring more business opportunities and growth and profitability of the Company, in the years ahead.

Dividend

The Board of Directors has not recommended any Dividend on the Equity Shares of the Company for the Financial Year ended 31st March, 2024.

Transfer to Reserves

The Board of Directors has not proposed to transfer any amount to the General Reserve.

Changes in Share Capital

The Authorized Share Capital of the Company was increased to Rs.15,00,00,000 (divided into 1,50,00,000 Equity Shares of Rs. 10/- each) and the Paid-up Share Capital has increased from Rs.9,95,00,000/- to Rs.13,95,00,000/- (divided into 1,39,50,000 Equity Shares of Rs.10/- each), in respect of the Initial Public Offering wherein the Company had issued and allotted 40,00,000 Equity Shares of Face Value Rs.10/- each issued at Rs.30/- in the Initial Public Offer of the Company.

The Company got listed on the NSE SME Board on June 30, 2023.

Material Changes and Commitments affecting the Financial Position of the Company which have occurred between 31st March, 2024 and 22nd August, 2024 (Date of the Report)

During the period under review, the Company had defaulted in the repayment of Cash Credit Facility availed and the bank has classified the account as NPA. The Management has made representation to the bank for the erroneously classification of the Account as NPA, which was made on technical grounds. The Board is discussing to pay the overdue and regularize the account.

Nature of Business

The Company is into the manufacturing of Pharmaceuticals Products and there has been no change in the nature of Business of the Company during the year.

Public Deposits

During the year under review, the Company has not accepted any deposit pursuant to the provisions of Sections 73 and 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

Annual Return

A copy of the Annual Return for the Financial Year 2023-2024 pursuant to the Sub-Section (3) of Section 92 of the Companies Act, 2013 read with Rule 11(1) of the Companies (Management and Administration) Rules, 2014 and forming part of this Report is placed on the website of the Company as per provisions of Section 134(3)(a) and is available at the following link: <http://www.vilinbiomed.co.in/>

Director's Responsibility Statement

In terms of Section 134 (5) of the Companies Act, 2013, the Directors would like to state that:

- i) In the preparation of the Annual Accounts, the applicable Accounting Standards have been followed.
- ii) The Directors have selected such Accounting Policies and applied them consistently and made judgements and estimates that were prudent so as to give a true and fair view of the State of Affairs of the Company at the end of the Financial Year and of the Profit or Loss of the Company for the Year under review.
- iii) The Directors have taken proper and sufficient care for the maintenance of adequate Accounting Records in accordance with the provisions of this Act for safeguarding the Assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) The Directors have prepared the Annual Accounts on a Going Concern basis.
- v) The Directors had laid down Internal Financial Controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively.
- vi) The Directors had devised proper system to ensure compliance with the provisions of all the applicable laws and that such system was adequate and operating effectively.

Directors and Key Managerial Personnel

a. Composition of Board of Directors of the Company:

As on 31st March, 2024 the Board has the following Directors:

Sl No	Name of Director	DIN	Designation
1	Mr. Veerareddy Vallapureddy	08061781	Non-Executive Independent Director
2	Mr. Rakesh Kumar Chandak	09849680	Non-Executive Independent Director
3	Mr. Viswa Prasad Sadhanala	08068933	Managing Director
4	Mr. Anuj Bajpai	08939135	Whole-Time Director
5	Ms. Padmaja Kalyani Sadhanala	03096445	Non-Executive Non-Independent Director

b. Changes in the KMP:

During the year, Ms. Ashdeep Kaur has resigned from the position of Company Secretary and Compliance Officer of the Company on February 24, 2024.

c. Changes after the year under review:

From the closure of the Financial Year (31st March, 2024) till the date of the Boards' Report (22nd August, 2024), the following changes took place on the Board/KMP of the Company:

SI No	Name of Director / KMP	Nature of Change	Date of Change
1	Ms. Padmaja Kalyani Sadhanala (DIN: 03096445) Non-Executive Director	Resignation	29/05/2024
2	Mr. Rakesh Kumar (DIN: 09849680) Independent Director	Resignation	22/08/2024
3	Ms. Aruna Madishetti (DIN: 10746293) Non-Executive Independent Director	Appointment	22/08/2024
4	Mr. Anand Lohia Company Secretary and Compliance Officer	Appointment	04/05/2024

d. Number of Meetings of the Board and Director's Attendance

During the year ended 31st March, 2024 Five (5) Board Meetings were held in accordance with the provisions of the Companies Act, 2013 and in compliance with the Secretarial Standards of the Institute of Company Secretaries of India (ICSI).

SI No	Date of the Meeting	Number of Directors entitled to attend the meeting	Number of Directors who attended the meeting
1.	May 10, 2023	5	5
2.	July 19, 2023	5	5
3.	August 24, 2023	5	5
4.	November 10, 2023	5	5
5.	February 8, 2024	5	5

The following Annual/ Extra Ordinary General Meetings were held, During the year under review:

SI No	Date of the Meeting	Purpose of the Meeting
1.	September 23, 2023	17 th Annual General Meeting of the Company

Formal Annual Evaluation

As per Section 149 of the Companies Act, 2013 the Independent Directors of the Company had a Meeting on February 8, 2024 without attendance of Non – Independent Directors and Members of the Management. In the Meeting, the following issues were taken up:

- Review of the performance of the Board as a whole;
- Review of the performance of the Chairperson of the Company, taking into account the views of Executive Directors and Non – Executive Directors;
- Assessing the Quality, Quantity and Timelines of flow of information between the Company Management and the Board, that is necessary for the Board to perform their duties effectively and reasonably.

The Meeting also reviewed and evaluated the performance of Non – Independent Directors.

The Meeting also reviewed and evaluated the performance the Board as whole in terms of the following aspects:

- Preparedness for Board / Committee Meetings
- Attendance at the Board / Committee Meetings

- Guidance on Corporate Strategy, Risk Policy, Corporate Performance and Overseeing Acquisitions and Disinvestments.
- Ensuring a Transparent Board Nomination Process with the diversity of Experience, Knowledge, Perspective in the Board.
- Ensuring the integrity of the Company's Accounting and Financial Reporting Systems, including the Independent Audit, and that appropriate systems of control are in place, in particular, systems for Financial and Operational Control and Compliance with the law and relevant Standards.

Declaration from Independent Directors on Annual Basis

The Company has received the declarations from Mr. Veerareddy Vallapureddy and Ms. Aruna Madishetti, Independent Directors of the Company to the effect that they are Meeting the criteria of Independence as provided in Sub-Section (6) of Section 149 of the Act and of Sub-Rule (1) and Sub-Rule (2) of the Rule 6 of the Companies (Appointment and Qualifications of Directors) Rules, 2014.

In the opinion of the Board, the Independent Directors possess the requisite integrity, expertise and experience (including the proficiency) of the independent Directors.

Statutory Auditors

M/s PPKG & Co, Chartered Accountants (FRN: 009655S) have been appointed as the Statutory Auditors of the Company for a term of five consecutive years till the conclusion of 22nd Annual General Meeting.

The said Auditors have carried out the Statutory Audit for the Financial Year 2023-2024. The Auditors Report for the Financial Year 2023-2024 does not contain any qualifications, reservations or adverse remark.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

Pursuant to provisions of Section 134 of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 the details of Conservation of Energy, Technology Absorption is attached herewith as "Annexure – A."

Foreign Exchange Earnings and Outgo: During the period under review, there was no Foreign Exchange Earnings or Outflow.

Secretarial Audit

Pursuant to provisions of Section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the Company had appointed Mr. Kashinath Sahu, Company Secretary in Practice to undertake the Secretarial Audit of the Company. The Secretarial Audit Report is annexed herewith as "Annexure – B."

During the year under review, there were no qualifications, reservations or adverse remarks reported by Secretarial Auditor under Section 204 of the Companies Act, 2013 in the course of the performance of his duties as Secretarial Auditor.

Management Discussion and Analysis

Pursuant to Regulation 34(2)(e) of the SEBI (LODR) Regulations, 2015, Report on Management Discussion and Analysis, is herewith annexed as "Annexure – C."

Internal Control Systems and their Adequacy

The Company has an in-house Internal Control System, commensurate with the size, scale and complexity of its operations. The Scope and Authority of the Internal Audit Function is defined in the Internal Audit Manual. To maintain its objectivity and independence, the Internal Audit Function reports to the Chairman of the Audit Committee of the Board and to the Chairman and Management.

The Internal Audit Department monitors and evaluates the efficacy and adequacy of Internal Control System in the Company, its compliance with Operating Systems, Accounting Procedures and Policies at all levels of the Company.

Based on the report of Internal Audit Function, process owners undertake corrective action in their respective areas and thereby strengthen the controls. Significant Audit observations and recommendations along with corrective actions thereon are presented to the Audit Committee of the Board.

Audit Committee

The Audit Committee was constituted in accordance with the provisions of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations with the following as Members of the Committee.

The Audit Committee comprises:

Name of Director	Status in Committee	Nature of Directorship
Mr. Veerareddy Vallapureddy	Chairman	Non-Executive Independent Director
Ms. Aruna Madishetti	Member	Non-Executive Independent Director
Mr. Viswa Prasad Sadhanala	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Audit Committee.

The terms of reference of our Audit Committee, in accordance with Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations.

Audit Committee Meetings and Attendance

Four Audit Committee Meetings were held during the year ended 31st March, 2024. The maximum time gap between any of the two meetings was not more than four months.

Date of the Meeting	Committee Strength	No. of Directors present
10.05.2023	3	3
24.08.2023	3	3
10.11.2023	3	3
08.02.2024	3	3

Nomination and Remuneration Committee

The Nomination and Remuneration Committee was constituted in accordance with the provisions of the Companies Act, 2013 and Regulation 19 of SEBI (LODR) Regulations. The Nomination and Remuneration Committee include the following:

Name of Director	Status in Committee	Nature of Directorship
Mr. Veerareddy Vallapureddy	Chairman	Non-Executive Independent Director
Ms. Aruna Madishetti	Member	Non-Executive Independent Director
Mr. Anuj Bajpai	Member	Whole-Time Director

The scope, functions and the terms of reference of the Nomination and Remuneration Committee is in accordance with the Section 178 of the Companies Act, 2013 read with Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nomination and Remuneration Committee Meetings and Attendance

The Nomination and Remuneration Committee has met once on 8th February 2024.

Date of the Meeting	Committee Strength	No. of Directors present
08.02.2024	3	3

Stakeholders Relationship Committee

The Stakeholders Relationship Committee was constituted in accordance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations. The Stakeholders Relationship Committee include the following:

Name of Director	Status in Committee	Nature of Directorship
Mr. Veerareddy Vallapureddy	Chairman	Non-Executive Independent Director
Ms. Aruna Madishetti	Member	Non-Executive Independent Director
Mr. Viswa Prasad Sadhanala	Member	Managing Director

The Company Secretary of the Company acts as the Secretary of the Stakeholders' Relationship Committee.

Stakeholders Relationship Committee Meetings and Attendance

The Stakeholders Relationship Committee has met once on 8th February 2024.

Date of the Meeting	Committee Strength	No. of Directors present
08.02.2024	3	3

Risk Management Committee

Regulation 21 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to forming of Risk Management Committee is not applicable to the Company during the Financial Year under review.

Corporate Governance and Shareholders Information

Pursuant to Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is not required to comply with the provisions of filing Corporate Governance Report to the Stock Exchange as it is not applicable to the Companies listed on the SME Platform.

Particulars of Loans, Guarantees or Investments under Section 186 of the Companies Act, 2013

The Company has not given any Loans nor provided Guarantee nor made any Investments during the Financial Year 2023-2024, which is beyond the limits as per Section 186 of the Companies Act, 2013.

Contracts or Arrangements with Related Parties under Section 188 (1) of the Companies Act, 2013

All the Contracts / Arrangements / Transactions entered by the Company, during the year under review, with Related Parties were in the ordinary course of business and at Arm's Length Basis. The particulars of such contracts or arrangements with Related Parties, pursuant to the provisions of Section 134(3)(h) and Rule 8 of the Companies (Accounts) Rules, 2014, in the prescribed Form AOC-2 is enclosed as "Annexure - D" to this Report.

All the Related Party Transactions were placed before the Audit Committee and also before the Board for their respective approval. Omnibus approval of the Audit Committee is obtained as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the transactions which can be foreseen and are repetitive in nature. The Company has developed a Policy on Related Party Transactions including the latest amendments thereof for the purpose of identification and monitoring of such transactions.

Policy on Preservation of the Documents

The Company has formulated a Policy pursuant to Regulation 9 of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ("Regulations") on Preservation of the Documents of the following type:

- documents whose preservation shall be permanent in nature;
- documents with preservation period of not less than eight years after completion of the relevant transactions

Vigil Mechanism

The Vigil Mechanism/Whistle Blower Policy has been adopted to provide appropriate Avenues to the employees to bring to the attention of the management, the concerns about any unethical behaviour by using the mechanism provided in the Policy. In cases related to financial irregularities, including fraud or suspected fraud, the employees may directly approach the Chairman of the Audit Committee of the Company. No Director or employee has been denied access to the Audit Committee. The web link for the policy is as follows: <http://www.vilinbiomed.co.in/>

Policy on criteria for determining Materiality of Events

The Company has adopted a Policy in accordance with the requirements of the Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations). The Policy is authorizing the Key Managerial Personnels of the Company for the purpose of determining materiality of an event or information of the Company and to ensure that such information is adequately disseminated in pursuance with the Regulations and to provide an overall Governance Framework for such determination of Materiality.

Policy on Directors' Appointment, Remuneration & Other Details

The Company's Remuneration Policy is directed towards the rewarding of performance based on review of achievements periodically. The Remuneration Policy is in consonance with the existing Industry practice.

The Company's Shareholders may refer the Company's website for the Remuneration Policy of the Company on the appointment and remuneration of Directors including criteria for determining qualifications, positive attributes, independence of a Director; and other matters provided under Sub-Section (3) of Section 178.

Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concerns Status and Company's Operations in future

The Company has not received any Significant or Material Orders passed by any Regulatory Authority, Court or Tribunal which shall impact the Going Concern Status and Company's Operations in future.

Details of Subsidiary Companies, Associates and Joint Venture Companies

The Company does not have any Subsidiary, Associate or Joint Ventures during the period under review.

Industrial Relations

Employee relations during the period under review continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees. It has taken various steps to improve productivity across the organization.

Business Risk Management

Business Risk Evaluation and Management is an ongoing process within the Organization. The Company has a robust Risk Management Framework to identify, monitor and minimize risks as also identify business opportunities. At present, the Company has not identified any element of risk which may threaten the existence of the Company.

Transfer of Amounts to Investor Education and Protection Fund

Your Company does not have any Unpaid or Unclaimed amounts lying for a period of seven years. Therefore, there were no Funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

Particulars of Employees

In terms of Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company does not have any Employee who is employed throughout the Financial Year and in receipt of Remuneration of Rs.120 Lakhs or more, or Employees who are employed for part of the year and in receipt of Rs.8.50 Lakhs or more per month.

Corporate Social Responsibility

The Provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility are not applicable to our Company

Maintenance of Cost Records

The Provisions relating to maintenance of Cost Records under Section 148 of Companies Act, 2013 are not applicable to the Company.

Insider Trading Regulations

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 1992 read with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Code of Conduct for prevention of Insider Trading and the Code for Corporate Disclosures ("Code"), as approved by the Board from time to time, are in force by the Company. The objective of this Code is to protect the interest of Shareholders at large, to prevent misuse of any price sensitive information and to prevent any Insider Trading activity by dealing in Shares of the Company by its Directors, Designated Employees and other Employees. The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, Designated Employees and other Employees from Trading in the Securities of Vilin Bio Med Limited at the time, when there is Unpublished Price Sensitive Information.

Obligation of Company under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

In order to prevent Sexual Harassment of Women at Workplace as per "The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013" has been notified. Under the said Act, every Company is required to set up an Internal Complaints Committee to look into complaints relating to sexual harassment at workplace of any women employee. As required under law, an Internal Compliance Committee has been constituted for reporting and conducting inquiry into the complaints made by the victim on the harassments at the workplace. During the year under review, no complaint of harassment at the workplace was received by the Committee.

Acknowledgement

Your directors take this opportunity to place on record the valuable co-operation and continuous support extended by its valued business associates, consultants, Auditors, Supplier, Customers, Banks / Financial Institutions, Government authorities and the shareholders for their continuously reposed confidence in the Company and look forward to having the same support in all its future endeavors.

Your directors also wish to place on record their sincere appreciation for significant contribution made by the employees at all the levels through their dedication, hard work and commitment, thereby enabling the Company to boost its performance during the year under report.

Date: 22nd August, 2024
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole-Time Director
(DIN: 08939135)

A. Conservation of Energy, Power and Fuel Consumption

Particulars	Current Year (2023-2024)	Previous Year (2022-2023)
1. Electricity (Purchased) Units		
Total Amount (Rs.)	12,04,000	13,64,000
Rate Per Unit (Rs.)	5.58	5.58
2. Electricity (Generated) Units		
Total Amount (Rs.)	--	--
Rate Per Unit (Rs.)	--	--
3. Total Units Consumed	215770	2,44,444

- a) Company ensures that the Manufacturing Operations are conducted in the manner whereby optimum utilization and maximum possible savings of energy is achieved.
- b) No specific investment has been made in reduction in energy consumption.
- c) As the impact of measures taken for conservation and optimum utilization of energy are not quantitative, its impact on cost cannot be stated accurately.

B. Technology Absorption

The Company's products are manufactured by using In-House Know-how and no outside technology is being used for manufacturing activities. Therefore, no technology absorption is required. The Company constantly strives for maintenance and improvement in quality of its products and entire activities are directed to achieve the aforesaid goal.

C. Foreign Exchange Earning and Outgo

Particulars	Current Year	Previous Year
Earnings	-	-
Outgo	-	-

Date: 22nd August, 2024
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole-Time Director
(DIN: 08939135)

FORM MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2024

(Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014)

To
The Members
Vilin Bio Med Limited

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Vilin Bio Med Limited** having CIN: **L24230TG2005PLC046689** and having Registered Office at Sy. No. 115/GF/J, Hanumanji Colony, Brig Sayeed Road, Bowenpally Hyderabad - 500009, Telangana (hereinafter called the Company). The Secretarial Audit was conducted in accordance with the guidance note issued by the Institute of Company Secretaries of India and in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other records maintained by the Company and also the information, confirmations, clarifications provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the Company has, during the audit period covering the Financial Year ended on 31st March, 2024 complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the Financial Year ended on 31st March, 2024, according to the provisions of:

- I. The Companies Act, 2013 (the Act) and the rules made there under;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- III. The Depositories Act, 1996 and the Regulations and Byelaws framed there under;
- IV. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings **(Not applicable to the Company during the period of Audit)**
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and The Securities Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers (Amendment) Regulations, 2013; **(Not applicable to the Company during the period of Audit)**
 - (b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; **(Not applicable to the Company during the period of Audit);**
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **(Not applicable to the Company during the period of Audit)**
 - (d) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **(Not applicable to the Company during the period of Audit)**
 - (e) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; **(Not applicable to the Company during the period of Audit)**
 - (f) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **(Not applicable to the Company during the period of Audit)**

- (g) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; ***(Not applicable to the Company during the period of Audit)***;
- (h) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; ***(Not applicable to the Company during the period of Audit)***
- (i) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; ***(Not applicable to the Company during the period of Audit)*** and
- (j) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018; ***(Not applicable to the Company during the period of Audit)***

VI. Other Laws specifically applicable to the Company as per the representations made by the Management include:

- a) Drugs & Cosmetics Act, 1940;
- b) Narcotic Drugs and Psychotropic Substances Act, 1985;
- c) Pharmacy Act, 1948
- d) Hazardous Waste Management Rules, 2016;
- e) National pharmaceutical Policy, 2012
- f) The Factories Act, 1948;
- g) Environ Protection Act, 1996
- h) Employees State Insurance Act, 1948
- i) Employees Provident Fund and Miscellaneous Provisions Act, 1952
- j) The Industrial disputes act, 1947;
- k) The Payment of Wages Act, 1936;
- l) The Minimum Wages Act, 1948;
- m) The Payment of Bonus Act, 1965;
- n) The Payment of Gratuity act, 1972.
- o) The Maternity Benefit Act, 1961.

We have relied on the representations made by the Company, its officers for systems and mechanism framed by the Company for compliances under other Acts, Laws and Regulations applicable to the Company as mentioned above.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by the Institute of Company Secretaries of India and notified under the Companies Act, 2013;
- (ii) The Listing Agreements entered by the Company with the Stock Exchange(s); ***(Not applicable to the Company during the period of Audit)***

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors/ Committees that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, Agenda and detailed notes on Agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the Meeting.

Majority decisions are carried through while the dissenting member's views, if any, are captured and recorded as part of the Minutes.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable Laws, Rules, Regulations and Guidelines.

We further report that the compliance by the Company of the applicable Financial Laws like Direct and Indirect Tax Laws and maintenance of Financial Records and Books of Accounts has not been reviewed in this Audit since the same have been subject to review by the Statutory Auditors and other designated professionals.

**For Kashinath Sahu & Co
Practicing Company Secretaries**

Date: 17th August, 2024

Place: Hyderabad

**SD/-
CS Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN: F004790F000996693
Peer Review No: 2957/2023**

This Report is to be read with our letter of even date, which is annexed as **Annexure – A** and forms an integral part of this Report.

Annexure – (i) to the Secretarial Audit Report

**To
The Members
Vilin Bio Med Limited**

Our report of even date is to be read along with this letter:

- Maintenance of Secretarial Records is the responsibility of the Management of M/s Vilin Bio Med Limited ("the Company"). Our responsibility is to express an opinion on these Secretarial Records based on our audit.
- We have followed the Audit Practices and Processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on to ensure that correct facts are reflected in the Secretarial Records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
- We have not verified the correctness and appropriateness of Financial Records and Books of Accounts of the Company.
- Wherever required, we have obtained the Management representation about the compliance of Laws, Rules and Regulations and happening of events etc.
- The compliance of the provisions of Corporate and other applicable Laws, Rules, Regulations, Standards is the responsibility of the Management. Our examination was limited to the verification of procedures on test basis.
- The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Practicing Company Secretaries**

**Date: 17th August, 2024
Place: Hyderabad**

**SD/-
CS Kashinath Sahu
Proprietor
FCS: 4790, CP: 4807
UDIN: F004790F000996693
Peer Review No: 2957/2023**

“ANNEXURE-C”

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis present the Industry overview, opportunities and threats, the Company's initiatives and overall strategy of becoming a market-driven service provider with various offerings. The Company is optimistic about capturing a substantial share of the global and domestic market amid the threats faced due to the liberalisation and increased competition from well-established companies from India and abroad.

Global Economic Outlook

The estimated value of the global (Contract Research Organization) CRO services market in revenue for 2023 is \$76.6 billion, with a projected growth to reach \$127.3 billion by 2028, representing a compound annual growth rate (CAGR) of 10.7% from 2023 to 2028. This growth is primarily attributed to factors such as the continuous expansion of pharmaceutical, biopharmaceutical, and medical device R&D pipelines, as well as technological advancements in the clinical trials process. Additionally, the increasing demand for novel clinical trial designs to support cell and gene therapies is expected to create growth opportunities for companies operating in this market.

The global pharmaceutical market is now estimated to be over USD 1.6 trillion and expected to grow at CAGR of about 6%

Though the pharmaceutical industry is developing at rapid pace, the pharmaceutical manufacturing companies are confronted with enormous challenges such as:

Cost & Pricing, New Medicines & Therapy dosages, changing regulatory landscape & growing digitization.

Indian pharma market is expected to grow to USD 130 Billion by 2030 thereby emerging as the 6 largest pharmaceutical market globally by absolute size. The growth of the pharmaceutical industry is globally driven by ageing population as well as about 1% increase in the global population at the same time

Indian Economy

India's GDP growth rate was 6.4% during FY 2023 due to a combination of factors such as expected global economic slowdown, strict monetary policies, and high oil prices. Despite these obstacles, India's growth rate remains higher than that of comparable economies, primarily due to strong domestic consumption and lower dependence on global demand.

The Indian pharmaceutical industry has been experiencing steady growth with a focus on generic medicines. It is expected that spending on pharmaceuticals in India will continue to increase, with a CAGR of 7.5–10.5% between 2023-27 to reach US\$ 35-39 Billion annually. The industry's continued focus on generics is a key factor to its growth, as they are typically priced lower than branded medicines. The industry's low-cost structure and its ability to produce large quantities of medicines have also made it a key player in the global pharmaceutical market.

India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most number of pharmaceutical manufacturing facilities that are in compliance with the US Food and Drug Administration (USFDA) and has 500 Active Pharma Ingredients (API) producers that make for around 8% of the worldwide API market.

Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with a potential to steer the industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the "pharmacy of the world" due to the low cost and high quality of its medicines.

Manufacturing

Our Sales Strategy is to sell our products in bulk to **Pharmaceuticals Manufacturers, Marketers and Traders**, who in turn provide the channel for sales to customers. Our products are primarily used by other pharmaceutical companies and traders, who ultimately will market it to the distributors and retail customers. We do not sell our products under any brand name. Following are our major products (manufacturing dosage forms):

- Oral Liquid (Syrups/Suspensions/Dry Powders (βeta & Non βeta-Lactam))
- Tablets & Capsules (βeta & Non βeta-Lactam).
- External Preparations

Opportunities, Threats and Outlook

Vilin Bio Med Limited will be able to place itself in a **strong position** by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization. The Company is looking at different opportunities in untapped markets and across a value chain. It plans for alliances with business associates in the Indian market, giving a huge boost to the selective products that it already deals in.

We are fully conscious of our responsibility toward our customers. Our efforts are directed toward the fulfillment of customer satisfaction through the quality of products. As the consolidation of this industry gains momentum, the need to develop a dedicated team of skilled manpower assumes urgency and importance.

We will continue to focus on training and motivation of manpower to develop teams of qualified and skilled personnel to effectively discharge their responsibilities in a number of projects and activities. It is, in this context, which we have been working towards promoting the skills and professionalism of our employees to cope with and focus on the challenges of change and growth.

Also, the majority of the new entrants in an already overcrowded market is the **major threat** to the Company. These can affect the profitability of established players in the short run. In the long run, however trusted players with strong brand equity will continue to prosper.

Internal control systems & their adequacy

The Company has strong and adequate internal control system suitable to its size and nature of business. We constantly upgrade our systems for incremental improvements. The Audit Committee of the Board regularly reviews our system. The systems ensure protection of assets and proper recording of transactions. Internal audit is carried out by an independent chartered accountants' firm on quarterly basis. The internal auditors' reports are regularly received by the Audit Committee. It is a regular practice to review the issues raised by statutory auditors by the Audit Committee.

“ANNEXURE D”

FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014).

Form for disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in subsection (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

1. Details of contracts or arrangements or transactions **not at arm's length basis.**

Sl. No	Name(s) of the related party and nature of relationship	Nature of contracts / arrangements/ transactions	Duration of the contracts/ arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Justification for entering into such contracts or arrangements or transactions	Date(s) of approval by the Board	Amount paid as advances, if any	Date on which the special resolution was passed in general meeting as required under first proviso to section 188
There were no contracts or arrangements or transactions entered into during the year ended 31st March 2024, which were not at arm's length basis.								

2. Details of material contracts or arrangement or transactions **at arm's length basis.**

Sl No	Name of the related party and nature of relationship	Nature of Contracts/ arrangements/ transactions	Duration of Contracts/ arrangements/ transaction	Salient terms of the contracts or arrangements or transactions including the value; if any;	Date of approval by the Board/ Shareholders, if any.	Amount incurred in Rs. in lakhs
1.	Redizen Lifesciences Private Limited	Trade Receivables	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	220.88
2.	Spectrogen Pharmachem Limited	Advance to Customers	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	449.37
3.	Blue Nile Capital Advisory Limited	Inter Corporate Loans	Regular	As per the agreement and in the Ordinary course of business	February 28, 2023	274.14
4.	Viswa Prasad Sadhanala	Remuneration			F.Y 2023-24	20.50

Date: 22nd August, 2024
Place: Hyderabad

By Order of the Board of Directors

Sd/-
Viswa Prasad Sadhanala
Managing Director
(DIN: 08068933)

Sd/-
Anuj Bajpai
Whole-Time Director
(DIN: 08939135)

ANNEXURE - E

CERTIFICATE OF COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

To
The Members,
VILIN BIO MED LIMITED

We have examined the compliance of conditions of Corporate Governance by VILIN BIO MED LIMITED (“the Company”), for the year ended on March 31, 2024, as stipulated in Regulation 15(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) for the period 1st April 2023 to 31st March 2024.

The compliance of conditions of Corporate Governance is the responsibility of Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the Financial Statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us by the Directors, officers and the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the abovementioned Listing Regulations.

We further state that, such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Company Secretaries**

**Date August 17, 2024
Place: Hyderabad**

**Sd/-
Kashinath Sahu
Practicing Company Secretary
FCS: 4790 CP: 4807
UDIN: F004790F000996704
Peer Review No. 2957/2023**

ANNEXURE - F

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members,
VILIN BIO MED LIMITED

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of VILIN BIO MED LIMITED having **CIN: L24230TG2005PLC046689**, Registered Office at Sy.No.115, Hanumanji Colony, Brig Sayeed Road, Bowenpally, Secunderabad, Telangana, 500009 (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V, Para-C, Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in, as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2024 have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sl No	Name of Director	DIN	Designation
1	Mr. Veerareddy Vallapureddy	08061781	Non-Executive Independent Director
2	Mr. Rakesh Kumar Chandak	09849680	Non-Executive Independent Director
3	Mr. Viswa Prasad Sadhanala	08068933	Managing Director
4	Mr. Anuj Bajpai	08939135	Whole-Time Director
5	Ms. Padmaja Kalyani Sadhanala	03096445	Non-Executive Non-Independent Director

Ensuring the eligibility for the appointment/continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is only to express an opinion on this as per our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**For Kashinath Sahu & Co
Company Secretaries**

**Date August 17, 2024
Place: Hyderabad**

**Sd/-
Kashinath Sahu
Practicing Company Secretary
FCS: 4790 CP: 4807
UDIN: F004790F000996715
Peer Review No. 2957/2023**

INDEPENDENT AUDITORS' REPORT

**TO
THE MEMBERS OF
VILIN BIO MED LIMITED.
HYDERABAD**

Report on the Audit of the Financial Statements

Opinion

We have audited the Financial Statements of **VILIN BIO MED LIMITED** ("the Company"), which comprise the balance sheet as at 31st March 2024, and the statement of profit and loss, and statement of cash flows for the period ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information [hereinafter referred to as "the Financial Statements"].

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its Profits, (*changes in equity*) and its cash flows for the period ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

"Information Other than the Financial Statements and Auditor's Report Thereon"

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report, but does not include the Financial Statements and our auditor's report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key Audit Matters are those matter that, in our professional judgement, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. During the year under consideration, we have no Key Audit Matters to report.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position and financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- (i) Planning the scope of our audit work and in evaluating the results of our work; and
- (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure A statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - (c) The Balance Sheet, the Statement of Profit and Loss, (the Statement of Changes in Equity) & Cash Flow statements dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - (e) On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164(2) of the Act.
 - (f) According to information and explanations given to us together with our audit examination, reporting with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls we give in Annexure B to the extent applicable.
 - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv.
- (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- v. No Dividend has been declared or paid during the year by the company, hence provisions of section 123 of the Companies Act, 2013, are not applicable.
- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software's. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

Place : Hyderabad
Date : 29/05/2024

for PPKG AND CO
Chartered
Accountants FRN No.
0009655S

Sd/-
GIRDHARI LAL
TOSHNIWAL (PARTNER)
M No. 205140
UDIN: 24205140BKALIZ2286

Annexure – A to the Independent Auditor’s Report of even date to the Members of M/s Vilin Bio Med Limited, on the Financial Statements for the Year ended March 31, 2024

Based on the audit procedures performed for the purpose of reporting a true and fair view on the Financial Statements of the Company and taking into consideration the information and explanations given to us and the Books of Accounts and other records examined by us in the normal course of Audit, and to the best of our knowledge and belief, we report that:

- 1)
 - a. The Company has maintained proper records showing full particulars, including quantitative details and situation of Fixed Assets,
 - b. The Company has a regular program of physical verification of its Fixed Assets under which Fixed Assets are verified in a phased manner over a period for which we have received the certificate of confirmation from the Management.
 - c. The Title Deeds of all the Immovable Properties (which are included under the head (‘Property, Plant and Equipment’) are held in the name of the Company.
 - d. The Company has not revalued any of its Property, Plant and Equipment’s during the year.
 - e. As per the information given to us there are no proceedings initiated or pending against the Company for holding any Benami Property under the Benami Transactions (Prohibition) Act, 1988 and Rules made there under.
- 2)
 - a. In our opinion and according to the information and explanation given to us, the Management has conducted physical verification of Inventory at reasonable intervals during the year, and no material discrepancies were noticed on the aforesaid verification, for which we have received the certificate of confirmation from the Management.
 - b. The Company has availed Financial Assistance from Bank or Financial Institutions.
- 3) The Company has not granted any Loans, secured or unsecured, to any Companies, Firms, Limited Liability Partnerships or other parties.
- 4) In our opinion, the Company has complied with the provisions of Section 186 in respect of the Investments and Loans. Further, in our opinion, the Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of Guarantees and Security.
- 5) In our opinion, the Company has not accepted any Deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- 6) As informed to us that the provisions of Section 148 are not applicable to the Company.
- 7)
 - (a) In our opinion, the Company has been regular in depositing undisputed statutory dues, including Goods and Services Tax, Income Tax, Sales Tax, Duty of Custom, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Income Tax, Sales Tax, duty of Custom, duty of Excise, Cess and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they become payable. However as per the information provided by the management, Provident Fund and Employees’ State Insurance is not applicable to the company for the current year.
 - (b) There is no Dues outstanding in respect of Income Tax, Sales Tax, Service Tax, Duty of Customs on account of disputes, whereas the company has intimations and Outstanding demands under Income Tax Act, 1961.
 - (c) According to the information and explanations given to us, the dues in respect of Sales Tax, Income Tax, Custom Duties, Wealth Tax, Excise Duty and Cess that have been deposited with the appropriate authorities except in cases where there is a dispute.

- 8) All the transactions recorded in the books of account have been disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as Income during the year in the Tax Assessments under the Income Tax Act, 1961 (43 of 1961).
- 9) According to the records of the Company examined by us and as per the information and explanations given to us, we hereby report that:
 - a. The Company has not defaulted in repayment of Loans or Borrowings to any Bank during the Year under review. The Company has No Outstanding Debentures during the year.
 - b. The Company is not declared Willful Defaulter by any Bank or Financial Institution or other Lender.
 - c. The Company has raised Term Loan from any Bank or Financial Institution during the current year.
 - d. To the extent of our check, no funds raised by the Company for short-term has been utilized for long term purposes.
 - e. The Company has not taken any funds from any entity or person on account of or to meet the obligations of its Subsidiaries, Associates or Joint Ventures.
 - f. The Company has not raised loans during the Year on the Pledge of Securities held in its Subsidiaries, Joint Ventures or Associate Companies.
- 10) The Company has raised the funds by way of Initial Public Offer in the month June, 2023. The Company has made an Allotment of 40,00,000 Equity Shares of Face Value Rs. 10 each issued at Rs. 30/-
- 11)
 - a. According to the information and explanations given to us, no material fraud by the Company or by its officers or employees has been noticed or reported during the course of Audit.
 - b. No Report under sub-section (12) of section 143 of the Companies Act has been filed by the Auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - c. No Whistle Blowers Complaints were received during the year under review. As represented to us by the Management, no Whistle Blowers Complaints were received during the year under review.
- 12) In our opinion, the Company is not a Nidhi Company, and accordingly, provisions of Clause 3(xii) of the Order are not applicable.
- 13) In our opinion, the Company is in compliance with Sections 177 and 188 of the Companies Act, 2013, with respect to applicable transactions with related parties, and the requisite details have been disclosed in the Financial Statements.
- 14) As per the information provided to us, the company does not have an adequate Internal Audit System.
- 15) In our opinion, the Company has not entered in any non-cash transactions with the Directors or persons connected with them covered under Section 192 of the Act. Accordingly, the provisions of Clause 3(xv) of the order are not applicable.
- 16)
 - a. According to the information and explanation given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and the Company has not conducted any NBFC Company during the year.
 - b. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.
- 17) The Company has not incurred cash losses in the Financial Year and in the immediately preceding Financial Year.
- 18) There has been no resignation of Statutory Auditors during the Financial year 2023-24.
- 19) On the basis of the Financial Ratios, ageing and expected dates of realization of Financial Assets and payment of Financial Liabilities, other information accompanying the Financial Statements, the Auditor's knowledge of the Board of Directors and the Management's plans, the Auditor is of the opinion that no material uncertainty exists as on the date of the Audit Report and that the Company is capable of meeting its Liabilities existing at the Date of Balance Sheet, as and when they fall due within a period of one year from the Balance Sheet Date. We however, state that this is not an assurance as to the future viability of the

Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- 20) The Company is not liable to contribute under Section 135 of the Companies Act, 2013. Accordingly, the provisions of Clause 3(xx) of the order are not applicable.
- 21) In our opinion and according to the information and explanations given to us, Company does not have any subsidiaries; associates and joint venture Therefore this clause is not applicable

For **PPKG & Co**
Chartered Accountants
Firm's Registration No. 009655S

Sd/-
Girdhari Lal Toshniwal
Partner
Membership No. 205140
UDIN: 24205140BKALIZ2286

Date: May 29, 2024
Place: Hyderabad

ANNEXURE - B TO THE AUDITORS' REPORT

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **VILIN BIO MED LIMITED**. ("The Company") as of 31 March, 2024 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company;

and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

for **PPKG AND CO**
Chartered Accountants

Place : **HYDERABAD**
Date : **29/05/2024**

Sd/-
GIRDHARI LAL TOSHNIWAL
5-8-352 ,701 7TH FLOOR, RAGHAVA RATNA TOWERS,
NEAR MEDWIN HOSPITAL, ABIDS, HYDERABAD-
500001 TELANGANA
UDIN: 24205140BKALIZ2286

BALANCE SHEET AS AT 31/03/2024

In ` Lakhs

Particulars	Note No.	as at 31/03/2024	as at 31/03/2023
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	1	1395.00	995.00
Reserves and surplus	2	889.00	72.76
Money received against share warrants		-	-
		2284.00	1067.76
Share application money pending allotment		-	-
Non-current liabilities			
Long-term borrowings	3	20.87	43.12
Deferred tax liabilities (Net)	4	8.16	7.00
Other Long term liabilities		-	-
Long-term provisions		-	-
		29.02	50.12
Current liabilities			
Short-term borrowings	5	662.12	450.00
Trade payables	6		
Total outstanding dues of micro enterprises and small enterprises		-	-
Total outstanding dues of creditors other than micro enterprises and small enterprises		195.34	118.94
Other current liabilities	7	11.89	26.43
Short-term provisions	8	58.01	54.33
		927.36	649.69
TOTAL		3240.38	1767.56
ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible Assets			
Property, Plant and Equipment	9	138.27	151.15
Intangible assets		-	-
Capital work-in-progress		-	-
Intangible assets under development		-	-
		138.27	151.15
Non-current investments		-	-
Deferred tax assets (net)		-	-
Long-term loans and advances	10	466.06	94.84
Other non-current assets	11	774.50	716.13
		1378.83	962.12
Current assets			
Current investments		-	-
Inventories	12	446.75	87.88
Trade receivables	13	568.41	560.05
Cash and cash equivalents	14	604.94	3.45
Short-term loans and advances	15	117.59	71.88
Other current assets	16	123.87	82.18
		1861.55	805.44
Accounting Policies and Notes on Accounts	1.0		
TOTAL		3240.38	1767.56

In terms of our attached report of even date

For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI
LAL
TOSHNIWAL
(PARTNER)

Sd/-
ANAND LOHIA

(COMPANY
SECRETARY)

Sd/-
CHILLAM
SRIKANTH

(CHIEF
FINANCIAL
OFFICER)

Sd/-
ANUJ
BAJPAI

(WHOLE
TIME
DIRECTOR)
(DIN: 08939135)

Sd/-
VISWA PRASAD
SADHANALA

(MANAGING
DIRECTOR)
(DIN: 08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN : 24205140BKALIZ2286

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31/03/2024

In ` Lakhs except earning per share

Particulars	Note No.	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Revenue from operations	17	1580.49	1231.30
Other income	18	32.43	2.44
Total Income		1612.92	1233.74
Expenses			
Cost of materials consumed	19	1279.55	709.53
Purchases of Stock-in-Trade		-	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	20	21.06	7.58
Employee benefits expense	21	80.38	77.74
Finance costs	22	78.58	64.84
Depreciation and amortization expense	23	13.01	16.76
Other expenses	24	117.83	179.12
Total expenses		1590.40	1055.58
Profit before exceptional and extraordinary items and tax		22.52	178.16
Exceptional items		-	-
Profit before extraordinary items and tax		22.52	178.16
Extraordinary Items		-	-
Profit before tax		22.52	178.16
Tax expense:	25		
Current tax		5.11	52.83
Deferred tax		1.16	0.84
Profit/(loss) for the period from continuing operations		16.24	124.50
Profit/(loss) from discontinuing operations		-	-
Tax expense of discontinuing operations		-	-
Profit/(loss) from Discontinuing operations (after tax)		-	-
Profit/(loss) for the period		16.24	124.50
Earnings per equity share:	26		
Basic		0.12	1.25
Diluted		0.12	1.25

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL

Sd/-
ANAND
LOHIA

Sd/-
CHILLAM
SRIKANTH

Sd/-
ANUJ
BAJPAI

Sd/-
VISWA
PRASAD
SADHANALA

(PARTNER)

(COMPANY
SECRETARY)

(CHIEF
FINANCIAL
OFFICER)

(WHOLE
TIME
DIRECTOR)

(MANAGING
DIRECTOR)

(DIN:
08939135)

(DIN:
08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN : 24205140BKALIZ2286

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2024

In ` Lakhs

Particulars	As at 31-Mar-2024	As at 31-Mar-2023
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	22.53	178.15
Adjustment For		
Depreciation	13.01	16.76
Foreign Exchange		
Gain or Loss on Sale of Fixed Assets		
Gain or Loss on Sale of Investment		
Finance Cost	78.58	
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
	91.59	16.76
Adjustment For working Capital Change		
Adjustment for Increase/Decrease in Inventories	(358.87)	140.50
Adjustment for Increase/Decrease in Trade Receivables	(8.36)	(208.74)
Adjustment for Increase/Decrease in Other Current Assets	(41.69)	(59.36)
Adjustment for Increase/Decrease in Other Non Current Assets	(58.37)	(289.16)
Adjustment for Increase/Decrease in Short Term Borrowings	212.12	
Adjustment for Increase/Decrease in Long term Loans and Advances	(371.22)	
Adjustment for Increase/Decrease in Short Term Loans and advances	(45.71)	(10.36)
Adjustment for Increase/Decrease in Trade Payables	76.40	54.82
Adjustment for Increase/Decrease in Other Current Liabilities	(14.54)	14.87
Adjustment for Provisions	3.68	50.33
Total Adjustment For Working Capital (B)	(606.56)	(307.10)
Total Adjustment to reconcile Profit (A+B)	(514.97)	(290.34)
Net Cash Flow from (Used in) Operations	(492.44)	(112.19)
Dividend Received		
Interest Received	(32.43)	
Interest Paid	-	
Income Tax Paid / Refund	(5.11)	(53.67)
Net Cash Flow from (used in) operation before Extra-ordinary Items	(529.98)	(165.85)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	(529.98)	(165.85)
Cash Flows from Investing Activities		
Proceeds from Fixed Assets		(2.95)
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	0.13	
Purchase of Investments or Equity Instruments		
Interest Received	32.43	

Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from losing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow from (Used in) in Investing Activities before Extra-ordinary Items	32.30	(2.95)
Proceeds from Extra Ordinary Items		
Payment for Extra Ordinary Item		
Net Cash Flow from (Used in) in Investing Activities	32.30	(2.95)
Cash Flows from Financial Activities		
Proceeds from Issue of Shares	400.00	204.00
Proceeds from Issuing shares for security premium	800.00	-
Proceeds from Issue of Debenture / Bonds / Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowing		(6.56)
Repayment of Borrowing	22.25	29.09
Dividend Paid		
Interest Paid	78.58	
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	1,099.17	168.35
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	1,099.17	168.35
Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	601.49	(0.45)
Effect of Exchange Rate change on Cash and Cash Equivalents		
Net Increase (Decrease) in Cash and Cash Equivalents	601.49	(0.45)
Cash and Cash Equivalents at beginning of period	3.45	3.90
Cash and Cash Equivalents at end of period	604.94	3.45

In terms of our attached report of even date

For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

Sd/-
GIRDHARI LAL TOSHNIWAL

(PARTNER)

Sd/-
ANAND LOHIA

(COMPANY
SECRETARY)

Sd/-
CHILLAM
SRIKANTH
(CHIEF
FINANCIAL
OFFICER)

Sd/-
ANUJ BAJPAI

(WHOLE
TIME
DIRECTOR)
(DIN:
08939135)

Sd/-
VISWA PRASAD
SADHANALA
(MANAGING
DIRECTOR)

(DIN: 08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN : 24205140BKALIZ2286

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2024

Note No. 1 Share Capital

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Authorised		
15000000 (9950000) Equity Shares of ` 10/- Par Value	1500.00	995.00
	1500.00	995.00
Issued		
13950000 (9950000) Equity Shares of ` 10/- Par Value	1395.00	995.00
	1395.00	995.00
Subscribed		
13950000 (9950000) Equity Shares of ` 10/- Par Value	1395.00	995.00
	1395.00	995.00
Paid-up		
13950000 (9950000) Equity Shares of ` 10/- Par Value Fully Paid-up	1395.00	995.00
	1395.00	995.00

Holding More Than 5%

Particulars	as at 31/03/2024		as at 31/03/2023	
	Number of Share	% Held	Number of Share	% Held
Sadhanala Venkata Rao	4589705	32.90	4589705	46.13
Srinivasa Reddy Devireddy	2012795	14.43	2012795	20.23
Viswa Prasad Sadhanala	1876140	13.45	1876140	18.86

Reconciliation of the number of Equity shares outstanding at the beginning and at the end of the reporting period

In ` Lakhs

Particulars	as at 31/03/2024		as at 31/03/2023	
	Number of Share	Amount	Number of Share	Amount
Number of shares at the beginning	9950000	995.00	3300000	330.00
Add : Issue	4000000	400.00	6650000	665.00
Less : Bought Back	0	0.00	0	0.00
Others	0	0.00	0	0.00
Number of shares at the end	13950000	1395.00	9950000	995.00

Shareholding of Promoters

Shares held by promoters as at 31/03/2023

Equity Shares of `10

Shares held by promoter at the end of year				% change during the year
SN	Promoters Name	No. of Shares	% of total shares	
1	Sadhanala Venkata Rao	4589705	46.13	32.31
2	Srinivasa Reddy Devireddy	2012795	20.23	14.04
3	Viswa Prasad Sadhanala	1876140	18.86	11.27
4	Ramesh Reddy Sama	463235	4.66	-0.96
5	Tanmayee Reddy Sama	21250	0.21	-18.53
6	Anuj Bajpai	15000	0.15	-20.64
7	Sama Ruchit Reddy	12500	0.13	-3.39
8	Sneha Bajpai	9375	0.09	-23.66

Note No. 2 Reserve and Surplus

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Capital Reserve - Opening	22.56	22.56
Addition	0.00	0.00
Deduction	0.00	0.00
	22.56	22.56
Securities Premium Opening	0.00	0.00
Additions	800.00	0.00
	800.00	0.00
Profit and Loss Opening	50.20	386.75
Amount Transferred From Statement of P&L	16.24	124.50
Amount Transferred From Sundries		
Others	0.00	(461.05)
	0.00	(461.05)
	66.44	50.20
	889.00	72.76

Note No. 3 Long Term Borrowings

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Term Loan		
Banks		
Secured		
Rupee		
PNB A/C 389800IL00000270 TERM LOAN A/C	20.87	43.12
	20.87	43.12

Note No. 4 Deferred Taxes

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Deferred Tax Liabilities		
Other	8.16	7.00
	8.16	7.00

Note No. 5 Short Term Borrowings

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Other loans and advances		
Secured		
PNB RAM NAGAR CC (16831 A/C)	474.22	450.00
KAPIL CHITS HYD PVT	43.18	0.00
MARGADARSI CHIT FUND PVT LTD	43.19	0.00
ICICI A/C NO.068005003833 A/C	101.53	0.00
	662.12	450.00

Note No. 6 Trade Payables

as at 31/03/2024

In ` Lakhs

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) MSME	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Others	80.65	114.69	0.00	0.00	0.00	195.34
(iii) Disputed dues-MSME	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed dues Others	0.00	0.00	0.00	0.00	0.00	0.00

as at 31/03/2023

In ` Lakhs

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) MSME	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Others	118.94	0.00	0.00	0.00	0.00	118.94
(iii) Disputed dues-MSME	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed dues Others	0.00	0.00	0.00	0.00	0.00	0.00

Note No. 7 Other Current Liabilities

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Other payables		
Other Current Liabilities		
SALARY PAYABLE	9.81	12.70
INTEREST PAYABLE	0.00	11.26
ESIC PAYABLE	0.03	0.03
E.P.F. PAYABLE	0.13	0.13
TDS PAYABLE	0.24	0.24
TDS 194Q@0.1% PURCHASES	0.05	0.05
POWER CHARGES PAYABLE	0.04	2.78
POWER PAYABLE FACTORY	1.50	0.00
CGST TAX	0.05	(0.38)
SGST TAX	0.05	(0.38)
DIRECTORS REMUNERATION PAYABLE	0.00	0.00
	11.89	26.43

Note No. 8 Short Term Provisions

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Tax Provision		
Current Tax		
INCOME TAX	56.94	52.83
Others		
AUDIT FEE PAYABLE	1.07	1.50
	58.01	54.33

No. 9 Property, Plant and Equipment

In ` Lakhs

Particulars	Gross					Depreciation					Impairment				Net	
	Openin g as at 01/04/ 2023	Addi tion	Dedu ction	Reval uatio n	Closin g as at 31/03 /2024	Openi ng as at 01/04 /2023	Duri ng Perio d	Dedu ction	Other Adj.	Closin g as at 31/03/ 2024	Open ing as at 01/0 4/20 23	Durin g Perio d	Rever sal	Closing as at 31/03/20 24	Closin g as at 31/03/ 2024	Closin g as at 31/03 /2023
Land																
Free Hold Land																
LAND	21.15				21.15										21.15	21.15
Total	21.15				21.15										21.15	21.15
Building																
Office Building																
BUILDING	39.86				39.86	25.68	1.45			27.13					12.73	14.18
BUILDING	19.15				19.15	13.19	0.62			13.81					5.34	5.96
BUILDING	22.36				22.36	15.87	0.68			16.54					5.81	6.49
BUILDING	34.10				34.10	28.65	0.45			29.10					5.00	5.45
BUILDING	37.44				37.44	30.99	0.51			31.50					5.94	6.45
BUILDING	129.76				129.76	103.16	2.74			105.91					23.85	26.60
BUILDING	43.68				43.68	36.12	0.74			36.86					6.82	7.56
BUILDING	22.65				22.65	11.05	1.15			12.20					10.46	11.60
Total	348.99				348.99	264.70	8.35			273.05					75.94	84.29
Plant and Machinery																
PLANT AND MACHINERY-1	201.15				201.15	188.76				188.76					12.39	12.39
PLANT AND MACHINERY-1	12.83				12.83	9.11	0.73			9.84					2.99	3.73
PLANT AND MACHINERY-1	0.92				0.92	0.65	0.05			0.70					0.22	0.27
PLANT AND MACHINERY-1	0.70				0.70	0.49	0.04			0.53					0.17	0.21
PLANT AND MACHINERY-1	8.00				8.00	5.69	0.46			6.15					1.85	2.31
PLANT AND MACHINERY-1	3.61				3.61	2.79	0.16			2.95					0.66	0.82
PLANT AND MACHINERY-1	2.85				2.85	0.10	0.18			0.28					2.57	2.75
PLANT AND MACHINERY-1	1.14				1.14	1.08				1.08					0.06	0.06
PLANT AND MACHINERY-1	0.18				0.18	0.17	0.00			0.17					0.01	0.01
PLANT AND MACHINERY-1	0.39				0.39	0.36	0.01			0.37					0.02	0.03
PLANT AND MACHINERY-1	0.40				0.40	0.35	0.01			0.36					0.04	0.05
PLANT AND MACHINERY-1	0.53				0.53	0.48	0.01			0.49					0.04	0.05
PLANT AND MACHINERY-1	4.16				4.16	3.48	0.14			3.62					0.54	0.68
PLANT AND MACHINERY-1	0.20				0.20	0.17	0.01			0.17					0.03	0.03
PLANT AND MACHINERY-1	0.34				0.34	0.22	0.02			0.24					0.10	0.13
PLANT AND MACHINERY-1	0.65				0.65	0.40	0.04			0.45					0.20	0.25
PLANT AND MACHINERY-1	0.34				0.34	0.22	0.02			0.24					0.10	0.12
PLANT AND MACHINERY-1	0.73				0.73	0.46	0.05			0.51					0.22	0.26
PLANT AND MACHINERY-1	0.35				0.35	0.23	0.02			0.25					0.10	0.12
PLANT AND MACHINERY-1	0.86				0.86	0.65	0.04			0.69					0.16	0.21
PLANT AND	88.16				88.16	83.75				83.75					4.41	4.41

MACHINERY-1																
PLANT AND MACHINERY-1	95.46				95.46	90.68				90.68					4.77	4.77
PLANT AND MACHINERY-1	57.18				57.18	53.36	0.96			54.32					2.86	3.82
PLANT AND MACHINERY-1	21.27				21.27	19.49	0.43			19.93					1.34	1.77
PLANT AND MACHINERY-1	3.93				3.93	3.33	0.12			3.45					0.47	0.59
PLANT AND MACHINERY-1	22.48				22.48	19.65	0.61			20.25					2.23	2.84
PLANT AND MACHINERY-1	1.96				1.96	1.77	0.05			1.81					0.15	0.20
PLANT AND MACHINERY-1	0.63				0.63	0.46	0.03			0.50					0.13	0.17
PLANT AND MACHINERY-1	0.51				0.51	0.38	0.03			0.41					0.10	0.13
PLANT AND MACHINERY-1	0.38				0.38	0.28	0.02			0.30					0.08	0.10
Total	532.29				532.29	489.04	4.24			493.28					39.01	43.25
Equipments																
Office Equipments																
OFFICE EQUIPMENT	0.29				0.29	0.28				0.28					0.01	0.01
OFFICE EQUIPMENT	0.44				0.44	0.42				0.42					0.02	0.02
OFFICE EQUIPMENT	2.93				2.93	2.78				2.78					0.15	0.15
Total	3.67				3.67	3.48				3.48					0.19	0.19
Computer Equipments																
COMPUTER	4.61				4.61	4.44				4.44					0.17	0.17
Total	4.61				4.61	4.44				4.44					0.17	0.17
Other Equipments																
PRINTER	0.11				0.11	0.00	0.06			0.07					0.04	0.10
Total	0.11				0.11	0.00	0.06			0.07					0.04	0.10
Furniture and Fixtures																
FURNITURE	0.15				0.15	0.11	0.01			0.13					0.03	0.04
FURNITURE	0.48				0.48	0.40	0.02			0.43					0.05	0.07
FURNITURE	2.46				2.46	2.33				2.33					0.12	0.12
FURNITURE	2.82				2.82	2.59	0.08			2.66					0.16	0.24
FURNITURE	6.55				6.55	5.83	0.22			6.05					0.49	0.72
FURNITURE	3.51				3.51	3.32				3.32					0.19	0.19
FURNITURE		0.13			0.13		0.01			0.01					0.12	
Total	15.96	0.13			16.09	14.59	0.34			14.93					1.16	1.38
Vehicles																
Motor Vehicles																
VEHICLE	10.77				10.77	10.23				10.23					0.54	0.54
VEHICLE	0.48				0.48	0.43	0.01			0.44					0.04	0.06
VEHICLE	0.45				0.45	0.43				0.43					0.02	0.02
Total	11.71				11.71	11.09	0.01			11.10					0.60	0.62
Grand Total	938.49	0.13	0.00	0.00	938.62	787.34	13.01	0.00	0.00	800.35	0.00	0.00	0.00	0.00	138.27	151.15
Previous	935.53	2.96	0.00	0.00	938.49	770.58	16.76	0.00	0.00	787.34	0.00	0.00	0.00	0.00	151.15	164.96

Note No. 10 Long-term loans and advances

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Loans and advances to related parties	274.14	94.84
Loans and advances to others	191.92	0.00
	466.06	94.84

Note No. 11 Other non-current assets

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Trade Receivable		
Secured, Considered Good		
Exceeding Six Months		
REDIZEN LIFESCIENCES PVT LTD., TELANGANA	220.88	220.26
RECON LIFE SCIENCES-DEBTORS	133.44	127.37
NATIONAL PHARMA, SAHARNAPUR	50.45	0.00
MATHRA LIFE SCIENCES	102.97	97.26
MANSA MEDI IMPEX, TELANGANA	2.85	2.85
MANCOP REMEDIES, TELANGANA	64.70	65.70
CHEMIST PHARMACEUTICAL, NANAUTA, SAHARANPUR	21.67	24.83
B.R. MEDICALS, HYD, TELANGANA	50.47	50.47
ALRED HEALTH CARE, HYDERABAD TELANGANA	50.34	50.67
ALRED HEALTH CARE LTD., HYD.	37.51	37.51
ALRED HEALTH CARE LTD, BANGLORE	39.22	39.22
	774.50	716.13

Note No. 12 Inventories

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Raw Material	74.03	30.51
Finished Goods	297.91	21.06
Others		
Packing Material	74.80	36.31
	446.75	87.88

Note No. 13 Trade receivables

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Trade Receivable		
Secured, considered good		
Within Six Months		
ZOIC LIFE SCIENCES, DEHRADUN	0.04	0.04
WAVES BIOTECH PVT LTD.	4.60	4.88
VLN MEDICALS, TELANGANA	1.27	1.27
VENTO PHARMACEUTICALS, ROORKEE	38.96	38.96
VEDAM LIFE SCIENCE, ROORKEE	12.22	12.22
VAM PHARMA, HARIDWAR	1.09	1.09
SYMPAR LIFE SCIENCES, DEHRADUN	1.29	1.29
STERIS HEALTH CARE, JAIPUR	0.16	0.16
SRI ANNAPURNA PHARMA	0.28	0.28
SPARSH REMEDIES PRIVATE LIMITED, DELHI	4.18	2.17
SHREYASH BIO PHARMA PRIVATE LTD.	0.15	0.15
SHREE JI MEDICOSE, KHATAULI	0.05	0.02
SAKET KANSAL AC	0.50	0.00
SAI KIRAN MEDICALS, A/C	0.50	0.50
RAJNI SHANKAR MEDICALS, WARANGAL	4.59	4.59
ONEROUS PHARMA	0.06	0.06
NOSME PHARMACEUTICAL, KARNAL	0.01	0.01
NITRO ORGANICS PRIVATE LIMITED	0.66	0.66
MORA PHARMA PRIVATE LIMITED	297.41	0.00
MESTRA PHARMA PRIVATE LIMITED, ROORKEE	23.07	16.57
MEDISHINE PHARMACEUTICALS PVT LTD.	1.20	1.20
MAA ANJANA DISTRIBUTORS, RAJASTHAN	0.30	0.30
LEE HEALTH DOMAIN INDIA PVT LTD., HYDERABAD	0.09	0.09
LAHAR PHARMACEUTICALS, HYDERABAD	(4.06)	0.41
KAMRON LABORATORIES LTD., AHMEDABAD	1.22	1.22

JKG HEALTHCARE, SAHARANPUR	0.05	0.05
HARI PRIYA MEDICALS	0.46	0.46
HANS PHARMA -DEBTORS	(519.26)	5.06
HANS PHARMA, ANDHRA PARDESH	1129.59	200.42
GUEST HOUSE RKE (ANITA SAINI W/O KANVAR PAL)	1.60	0.00
EXCELLENT TRADERS, ROORKEE	0.00	0.00
EMPIRE HEALTH CARE, TELANGANA	12.38	12.38
C ZEN LIFESCIENCES, TELANGANA	(11.05)	0.55
BIOGENETICS HEALTH CARE(INDIA) PVT. LTD, KOLKATTA	0.81	0.81
BIOCLARIS DRUGS & PHARMACEUTICALS, ROORKEE	5.53	5.53
ANCONA PHARMACEUTICALS	4.43	4.43
ALRIC BIO MEDICS, OLD A/C TELANGANA	0.14	0.14
AARMED FORMULATION PVT. LTD., AHMEDABAD	3.24	3.24
SPECTROGEN INTERNATIONAL PRIVATE LIMITED	(449.37)	238.84
	568.41	560.05

Ageing Schedule as at 31/03/2024

Particulars	Outstanding for following periods from due date of payment						Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) Undisputed Trade receivables - considered good	477.28	91.13	0.00	0.00	0.00	0.00	568.41
(ii) Undisputed Trade Receivables - considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iii) Disputed Trade Receivables considered good	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed Trade Receivables considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Ageing Schedule as at 31/03/2023

Particulars	Outstanding for following periods from due date of payment						Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Not due	
(i) Undisputed Trade receivables - considered good	555.21	4.84	0.00	0.00	0.00	0.00	560.05
(ii) Undisputed Trade Receivables - considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iii) Disputed Trade Receivables considered good	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(iv) Disputed Trade Receivables considered doubtful	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Note No. 14 Cash and cash equivalents

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Cash in Hand	4.83	2.92
Balances With Banks		
Balance With Scheduled Banks		
Current Account		
ICICI BANK - 630805161779	0.11	0.00
PNB CURRENT AC NO-3898002100017782	0.00	0.02
PNB CURRENT ACCOUNT A/C NO.3898002100013041	0.00	0.00
P.N.B CURRENT A/C NO. - 3898002100013041	0.00	0.05
ICICI A/C NO.068005003833 A/C	0.00	0.46
Deposit Account		
FIXED DEPOSIT	600.00	0.00
	604.94	3.45

Note No. 15 Short-term loans and advances

In ` Lakhs

Particulars	as at 31/03/2024	as at 31/03/2023
Security Deposits		
Secured, considered good		
DEPOSIT	2.00	2.00
ELECTRICITY SECURITY	2.85	2.85
RENT DEPOSIT	1.50	1.50
Loans and advances to related parties		
Loans and advances to others		
Secured, considered good		
A.S TRADING COMPANY	0.00	0.81
AASTHA MEDI SOLUTIONS, BHAGWANPUR, ROORKEE	0.00	0.51
AAY WON LAMITUBES & PACKING SOLUTION, H.P.	0.02	0.02
AIRCON ENGINEERS, DELHI	0.08	0.08
ANMOL CORRUPACK P LTD, BHAGWANPUR RKE	(0.29)	0.25
ASG PHARMA, ROORKEE	0.10	0.10
AYANSH ENTERPRISES, ROORKEE	0.01	0.01
BASHAR TRADERS, ROORKEE	0.02	0.02
FAIR COMMUNICATION & SERVICES, RKE	0.00	1.08
GAUR ENTERPRISES, GHAZIABAD	0.28	0.28
GUJRAT TRADING CORPORATION, ROORKEE	0.00	0.00
J K AARNA PRINTING & PACKERS, MANGLORE, ROORKEE	0.02	0.02
KOCHER PACKAGING INDUSTRIES, HARIDWAR	0.09	0.09
KUNDAN SALE COP.	(0.14)	0.11
LEROI PHARMACEUTICALS PVT. LTD, MANGLORE, RKE.	0.10	0.10
MAA LAXMI CHEMICALS, ROORKEE	0.00	0.00
MOHIT ARORA & CO. RKE	0.12	0.12
MONY CHEMICALS, GHAZIABAD	0.02	0.02
NEW AMBEY PACK, RKE.	0.12	0.12
PIYUSH TRADING CO.,	0.02	0.02
PRAGATI RAW PHARMA PVT. LTD, RKE.	0.07	0.07
PRECIOUS PHARMA, MUMBAI	0.00	0.50
R.S. ENTERPRISES, ROORKEE	0.05	0.05
RAJSHI FARMA PVT. LTD., HARIDWAR	0.01	0.01
SAINI PRINTING & PACKERS, ROORKEE	0.01	0.01
SEA SHELL CHEMICALS PVT. LTD.	0.06	0.06
SHREE BALAJI ENTERPRISES, ROORKEE	0.26	0.26
SHRI GANESH PRINTERS, ROORKEE	0.00	0.07
SHRI RADHEY PRINTERS, BHAGWANPUR	0.02	0.02
WINMARK GRAPHIX, SAHARANPUR	0.03	0.03
YACCA PHARMACEUTICALS PVT. LTD., RKE	0.01	0.01
DEVALAPALLI ARUNA	5.00	5.00

DHEERAJ MADAN A/C.	2.00	2.00
NANDINI MITTAL A/C	5.50	5.50
ROHIT KUMAR A/C	8.27	8.27
SREEKANTH REDDY SIR	35.95	35.95
INDO GERMAN REMEDIES, MEERUT	0.00	1.18
KAHAN PHARMACEUTICALS	0.00	0.50
MULTANI PHARMACEUTICALS LIMITED, RKE	(0.32)	0.03
SHRI LAXMI BHAWANI AGENCIES, ROORKEE	0.00	0.62
SINGH YUDHVEER & ASSOCIATES, RKE/	0.00	1.62
UP ENGINES SERVICES, HARIDWAR-ADVANCE	0.18	0.00
ANUPAMA AC	0.10	0.00
JADALA RAMESH	0.25	0.00
RAMBABU A/C	0.10	0.00
SUVARNA LATHA	0.10	0.00
POLLUTION SECUIRTY	0.04	0.00
PRADEEP REDDY SHARE ACCOUNT	25.00	0.00
SHREE GANESH PRINTERS, ROORKEE	0.07	0.00
SOURAV MATHUR A/C.	(1.08)	0.00
VISHWA PRASAD	25.00	0.00
ANUJ BAJPAI	4.00	0.00
	117.59	71.88

Note No. 16 Other current assets	In ` Lakhs	
Particulars	as at 31/03/2024	as at 31/03/2023
TDS RECEIVABLE	3.47	0.23
TCS 0.1% A/C	0.13	0.09
SALONI SHARMA ADVANCE	0.15	0.15
SALARY ADVANCES	0.12	0.12
REVERSE TAX CHARGES PAYABLE	0.00	0.16
REVERSE TAX CHARGES	0.00	0.82
PUBLIC ISSUE ACCOUNT	3.24	0.00
P. RAVIKIRAN A/C	0.08	0.08
NISHANT SHARMA A/C	0.05	0.05
NATIONAL SECURITY DDEPOSITORY LTD	(0.04)	0.02
MISC.EXPENDITURE	31.68	32.10
GUGULOTHU RAGHU A/C	0.35	0.35
G. MARUTI A/C	4.51	2.50
CHENNUR SAILOO	0.26	0.26
ARJUN DIXIT A/C.	0.10	0.10
AKHIL KM. ASS. CLPC HRW	0.28	0.28
AJAY KARANWAL	0.09	0.09
AARTI MATHUR A/C	0.15	0.15
IGST	0.00	44.66
CGST INPUT RECEIVABLE	7.92	0.00
SGST INPUT RECEIVABLE	71.36	0.00
	123.87	82.18

Note No. 17 Revenue from operations

Particulars	In ` Lakhs	
	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Sale of Products	1580.49	1231.30
	1580.49	1231.30

Note No. 18 Other income

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Miscellaneous	32.43	2.44
	32.43	2.44

Note No. 19 Cost of materials consumed

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Raw Material		
Opening	66.82	199.74
Purchase	1659.48	515.69
Adjustment	0.00	60.92
Closing	446.75	66.82
	1279.55	709.53
	1279.55	709.53

Details of Raw Material

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
RAW MATERIAL	1279.55	709.53
	1279.55	709.53

Note No. 20 Changes in inventories of finished goods, work-in-progress and Stock-in-Trade

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Opening		
Finished Goods	21.06	21.09
	21.06	28.64
Closing		
Finished Goods	0.00	21.06
	0.00	21.06
Increase/Decrease		
Finished Goods	21.06	0.03
	21.06	7.58

Details of Changes in Inventory

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Finished Goods		
FINISHED GOODS	21.06	0.03
Work in Progress		
WIP	0.00	7.55
	21.06	7.58

Note No. 21 Employee benefits expense

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Salary, Wages & Bonus	79.07	74.09
Staff Welfare Expenses	1.31	3.65
	80.38	77.74

Note No. 22 Finance costs

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Interest Expenses		
Interest Expenses	75.22	62.14
Bank Charges	2.82	2.71
Finance Charges		
Other Finance Charges	0.54	0.00
	78.58	64.84

Note No. 23 Depreciation and amortization expense

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Depreciation & Amortization		
Depreciation Tangible Assets	13.01	16.76
	13.01	16.76

Note No. 24 Other expenses

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Administrative and General Expenses		
Telephone Postage	0.61	0.40
Printing Stationery	0.65	0.38
Rent Rates And taxes	0.75	0.00
Auditors Remuneration	1.25	1.50
Repairs Maintenance Expenses	2.46	9.25
Travelling Conveyance	0.00	2.52
Legal and Professional Charges	0.81	14.18
Insurance Expenses	0.58	0.76
Vehicle Running Expenses	0.00	0.03
Safety and Security Expenses	5.54	6.74
Other Administrative and General Expenses	25.33	104.54
Selling Distribution Expenses		
Advertising Promotional Expenses	0.29	0.00
Other Selling Distribution Expenses	0.00	2.00
Write off Assets and Liabilities		
Other Write Offs	73.66	10.83
Other Expenses	5.90	26.01
	117.83	179.12

Note No. 25 Tax expense

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Current tax	5.11	52.83
Deferred tax	1.16	0.84
	6.27	53.67

Note No. 26 Earnings per equity share

In ` Lakhs

Particulars	For the Year Ended 31/03/2024	For the Year Ended 31/03/2023
Earnings Per Equity Share		
Basic	0.12	1.25
Diluted	0.12	1.25
Number of Shares used in computing EPS		
Basic	139.5	99.5
Diluted	139.5	99.5

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN: 009655S

For VILIN BIO MED LIMITED

GIRDHARI LAL TOSHNIWAL

(PARTNER)

ANAND LOHIA	CHILLAM SRIKANTH	ANUJ BAJPAI	VISWA PRASAD SADHANALA (MANAGING DIRECTOR)
(COMPANY SECRETARY)	(CHIEF FINANCIAL OFFICER)	(WHOLE TIME DIRECTOR)	(DIN: 08068933)
		(DIN: 08939135)	

Place : Hyderabad
Date : 29/05/2024
UDIN: 24205140BKALIZ2286

Notes on Financial Statements for the Financial year ended on March 31, 2024

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

1. General information

Vilin Bio Med Limited ('the Company') is engaged in the business of manufacturing and selling pharmaceutical products.

The company is a public limited company incorporated under Companies Act, 2013 and domiciled in India bearing CIN No: L24230TG2005PLC046689 and has its registered office at Sy no 115, Hanumanji Colony, Opp Sub Register Office, Old Bowenpally, Secunderabad - 500003, Hyderabad, Telangana - India. Its share are listed on the NSE SME EMERGE.

2. Significant Accounting policies

(a) Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP). These financial statements have been prepared to comply in all material respects with the Accounting Standards notified by Companies (Accounting Standards) Rules, 2006, (as amended) and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared under the historical cost convention on an accrual basis and going concern basis. The accounting policies have been consistently applied by the company are consistent with those used in the previous year.

(a) Use of estimates

The preparation of Financial Statements in conformity with the Generally Accepted Accounting Principles requires the Management to make estimates, judgements, and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period.

Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcome requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(b) Functional and Presentation Currency

The Financial Statements are prepared in Indian Rupees ("INR") which is the Company's Functional Currency for its Operations. All Financial Information presented in INR has been rounded to the nearest 'Lakhs' with two decimal places, unless stated otherwise.

(c) Recognition of Revenue and Expenditure

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria is ensured before revenue is recognized.

Income from services

Revenue from services contracts priced on time and material basis are recognized when services are rendered and related costs are incurred. The Company collects Goods and Services Tax on behalf of the government and therefore it is not an economic benefit flowing to the Company. Hence, it is excluded from revenue.

(d) Sale of goods

Revenue is measured at the transaction price of the consideration received or receivable. Revenue from Sale of products is recognized when the control on the Goods have been transferred to the Customer. The Performance Obligation in case of sale of product is satisfied at a point in time i.e., when the material is shipped to the customer or on delivery to the customer, as may be specified in the Contract.

(e) Interest income

Interest Income is recognized on a time proportion basis taking into account the amount outstanding and the effective interest rate method. Interest Income is included under the head "Other Income" in Statement of Profit and Loss.

(f) Property, Plant and Equipment (PPE)

i. Recognition and measurement

Property, Plant and Equipment are stated at Cost comprising of Purchase Price and any initial directly attributable cost of bringing the Asset to its working condition for its intended use less Accumulated Depreciation and Impairment Loss, if any

(a) Subsequent expenditure

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

(b) Depreciation

Depreciation on fixed assets is provided on Written Down Value method (WDV) as per Useful life of Asset and in the manner prescribed in Schedule II of the Companies Act, 2013.

(g) Intangible assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortisation/depletion. All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets are capitalized.

The Company has elected to continue with the carrying value of all its intangible assets as recognized in the financial statements as at the date of transition, measured as per the previous GAAP and use that as the deemed cost as at the transition date.

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific to which it relates.

(h) Impairment of non-financial assets

Assets that have a definite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired.

The recoverable amount is higher of the asset's net selling price or value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss for an asset is reversed if, and only if, the reversal can be related objectively to an event occurring after the impairment loss was recognized. The carrying amount of an asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

(i) Borrowing cost

Borrowing costs attributable to the acquisition/construction of qualifying assets are capitalized and form part of the cost of the qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue as an expense.

(j) Income Tax

Provision for income tax is made for both current and deferred taxes. Provision for current income tax is made on the current tax rates based on the assessable income. The Company provides deferred tax based on the tax effect of timing differences resulting from the recognition of items in the financial statements and in estimating its current tax provision. Deferred tax assets are recognized where there is certainty that there will be sufficient future taxable income available against which such deferred tax assets can be realized.

(k) Inventories

Inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective present location and condition. Cost of raw materials, work-in- progress, packing materials, trading and other products are determined on first-in-first-out basis.

(l) Research and development

Revenue expenditure on Research and Development is charged to Profit and Loss Account as incurred. Capital expenditure on assets acquired for Research and Development is added to Property, Plant and Equipment (PPE).

(m) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets Classification

The Company shall classify financial assets as subsequently measured at amortised cost and fair value through profit and loss (FVTPL) on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

Initial recognition and measurement

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date i.e., the date that the Company commits to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

(n) Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term deposits with banks with an original maturity of three months or less.

(o) Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost. Gains and losses are recognized in profit and loss when the liabilities are derecognized. This category generally applies to interest-bearing loans and borrowings.

(o) Foreign currency transactions

Initial recognition

Foreign currency transactions are recorded in the reporting currency by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are retranslated using the exchange rate prevailing at the reporting date. Non-monetary items, which are measured in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction. Non-monetary items, which are measured at fair value or other similar valuation denominated in a foreign currency are translated using the exchange rate at the date when such value was determined.

Treatment of exchange differences

Exchange differences arising on settlement/restatement of foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the statement of profit and loss.

(q) Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased item, are classified as operating leases. Operating lease payments are recognized as an expense in the Statement of Profit and Loss on a Straight – line basis over the lease term.

(r) Employee benefits

All Employee Benefits payable for rendering the service such as Salaries, Wages etc. and the expected cost of ex-gratia are recognized in the period in which the employee renders the related service. A Liability is recognized for the amount expected to be paid when there is a present legal

or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

(s) Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognized when the Company has a Present Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognized in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Entity. Contingent Assets are not recognized in Financial Statements and are disclosed in the Notes when it is virtually certain that economic benefits will inflow to the Company.

(t) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

27. Related Party disclosure as required by Accounting standard (AS) 18 “Related Party Disclosure”

I) Related Party Disclosures with whom transaction have been taken place during the year.

a) Key Management Personnel (KMP)

Mr. S Viswa Prasad (Managing Director), Mr. Anuj Bajpai (Whole Time Director), Srikant Chilam (Chief Financial Officer) w.e.f. 17th December, 2022, Anand Lohia (Company Secretary and Compliance Officer) w.e.f. 04th May, 2024.

Significant Related Party Transaction with Related Parties during the year:

(In Lakhs)

Sr. No	Party Name	Relationship	Nature of Transactions	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
1.	Viswa Prasad Sadhanala	Managing Director (w.e.f. 01.10.2022)	Advances	13.50	
2.	Viswa Prasad Sadhanala	Managing Director (w.e.f. 01.10.2022)	Remuneration	7.00	4.5
3.	Spectrogen International Private Limited	Enterprises-KMP having significant influence/owned by major shareholder	Trade Receivable	-	238.84
4.	Spectrogen International Private Limited	Enterprises-KMP having significant influence/owned by major shareholder	Advance to Customers	449.37	-
5.	Redizen Lifesciences Private Limited	Enterprises-KMP having significant influence/owned by major shareholder	Trade Receivable	220.88	220.26
6.	Blue Nile Capital Advisory Limited	Enterprises-KMP having significant influence/owned by major shareholder	Current Assets	274.14	94.84

28. Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders.

The Company monitors capital using a ratio of 'net debt' to 'equity'. For this purpose, net debt is defined as total debt, comprising loans and borrowings less cash and cash equivalents and current investments.

The Company's net debt to equity ratio as at 31st March 2024 and 31st March 2023 was as follows

Particulars	(` In Lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
Current Borrowings	682.99	493.12
Gross Debt	682.99	493.12
Less - Cash and Cash Equivalents	604.95	3.45
Less - Current Investments	-	-
Net debt	78.04	489.67
Total equity	2284.00	1067.76
Net debt to Equity ratio*	0.034	0.46
*Since Net debt to Equity ratio result is negative, the same is shown as nil.		

29. Earning Per Share (EPS):

Basic EPS and Diluted EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the company by the weighted average number of Equity shares outstanding during the year.

Particulars	(` in Lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
Profit attributable to equity holders	16.24	124.50
Weighted average number of shares outstanding during the year	139.5	99.5
Nominal Value of Equity Shares (in Rs.)	10	10
Earning Per Share Basic and Diluted (in Rs.)	0.12	1.25

30. As at 31st March, 2024, the Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

	Year ended 31st March, 2024	Year ended 31st March,2023
a) The principal amount remaining unpaid to any supplier at the end of the year	0	0
b) Interest due remaining unpaid to any supplier at the end of the year	0	0
c) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the year	0	0

d) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006	0	0
e) The amount of interest accrued and remaining unpaid at the end of each accounting year	0	0
f) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprises, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	0	0

Disclosure of payable to vendors as defined under the “Micro, Small and Medium Enterprise Development Act, 2006” is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue principal amounts / interest payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard in respect of payment made during the year or on balance brought forward from previous year.

31. Trade Receivables Ageing Schedule:

Particulars	As at 31st March, 2024					
	Less than 6 Months	6 months - 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
i) Undisputed Trade Receivables - Consider Good	477.28	91.13	-	-	-	568.41
ii) Undisputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
iv) Disputed Trade Receivables - Consider Good	-	-	-	-	-	-
v) Disputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
vi) Disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	477.28	91.13	-	-	-	568.41

Particulars	As at 31st March, 2023					
	Less than 6 Months	6 months - 1 Year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Undisputed Trade Receivables - Consider Good	555.21	4.84	-	-	-	560.05
(ii) Undisputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
(iv) disputed Trade Receivables - Consider Good	-	-	-	-	-	-
(v) disputed Trade Receivables - Which have Significant Increase In Credit Risk	-	-	-	-	-	-
(vi) disputed Trade Receivables - Credit Impaired	-	-	-	-	-	-
Total Debtors	555.21	4.84	-	-	-	560.05
Less: Provision for Doubtful Debts					-	-
Net Debtors	555.21	4.84	-	-	-	560.05

32. Trade Payable Ageing Schedule:

Particulars	As at 31st March, 2024				
	Less than one year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Micro enterprises and small enterprises	80.65	114.69	-	-	195.34
(ii) Others					
(iii) Disputed dues -Micro enterprises and small enterprises	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-
Total	80.65	114.69			195.34

Particulars	As at 31st March, 2023				
	Less than one year	1-2 Years	2-3 Years	More Than 3 Years	Total
(i) Micro enterprises and small enterprises	-	-	-	-	-
(ii) Others	54.82	64.12	-	-	118.94
(iii) Disputed dues -Micro enterprises and small enterprises	-	-	-	-	-
(iv) Disputed dues- Others	-	-	-	-	-
Total	54.82	64.12	-	-	118.94

33. Capital commitment and contingent liabilities

a) Capital commitment

There are no capital commitment outstanding as at reporting date (as at March 31, 2024: NIL)

b) Contingent Liabilities and Commitments

There are no contingent liabilities

34. OTHER STATUTORY INFORMATION:

- (i) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
- (ii) The Company has not granted Loans or Advances in the nature of loans to promoters, directors, KMPs and the related parties.
- (iii) The Company does not have any transactions with companies which are struck off.

35. The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns of the Company is primarily determined by the nature of products and services. Consequently, the geographical segment has been considered as a secondary segment.

The business segment has been identified on the basis of the nature of products and services, the risks and returns, internal organization and management structure and the internal performance reporting systems. The business segment comprises of manufacturing and selling of pharmaceutical products. Geographical segment is considered based on sales within India and outside India.

36. Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

In terms of our attached report of even date
For PPKG AND CO
CHARTERED ACCOUNTANTS
FRN : 009655S

For VILIN BIO MED LIMITED

GIRDHARI LAL TOSHNIWAL

(PARTNER)

ANAND LOHIA	CHILLAM SRIKANTH	ANUJ BAJPAI	VISWA PRASAD SADHANALA (MANAGING D IRECTOR)
(COMPANY SECRETARY)	(CHIEF FINANCIAL OFFICER)	(WHOLE TIME DIRECTOR)	(DIN : 08068933)

Place : Hyderabad
Date : 29/05/2024
UDIN: 24205140BKALIZ2286

Vilin Bio Med Limited